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ABSTRACT
EXPRESSION AND FUNCTION OF ZEBRA:




Epstein-Barr virus (EBV) encodes a protein, ZEBRA, 
which enables the virus to switch from a latent to a lytic 
life cycle. ZEBRA expression was studied in lymphoid cells 
harboring either standard virus or a mixture of standard and 
defective viruses. ZEBRA protein could not be detected in 
cells latently infected with standard EBV but was 
constitutively expressed in cells containing both defective 
and standard EBV genomes. Experiments indicated that 
regulation of transcription of the ZEBRA gene (BZLFl) is a 
pivotal event in the control of EBV replication. ZEBRA 
specific BZLFl transcripts were spontaneously expressed in 
cells harboring defective virus but were only synthesized by 
the latent virus after chemical induction. BZLFl 
transcription was sensitive to inhibition of protein 
synthesis but not to inhibition of lytic viral DNA 
synthesis. This suggests that ZEBRA is an early replicative 
protein whose expression is dependent on the synthesis of a 
viral or cellular factor.
The basic domain of the ZEBRA protein is homologous to 
the Fos/Jun oncogene family and shares their ability to bind
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the canonical AP-1 site (TGAGTCA). However, ZEBRA does not 
contain a leucine zipper domain; a motif necessary for DNA 
binding of Fos/Jun proteins. Additionally, ZEBRA binds to 
sites which deviate from the AP-1 consensus sequence. Thus, 
it was of interest to study the DNA binding properties of 
the ZEBRA protein.
Deletional mutagenesis of the BZLFl cDNA indicated that 
amino acids 172-227, representing the basic and putative 
dimerization domains, were required for specific binding to 
AP-1 and divergent sites. Mutagenesis of three basic amino 
acids, which are conserved in Fos, abrogated ZEBRA binding 
to all target sequences. Additionally, ZEBRA was determined 
to bind DNA as a homodimer.
DNA binding studies of ZEBRA and a Fos-GCN4 chimera 
indicated that although these proteins have homology in 
their basic DNA binding domains, they have different cognate 
binding specificities. The autoregulated BZLFl promoter 
contains three divergent AP-1 sequences; Fos-GCN4 uniquely 
recognized one of the sites while ZEBRA bound only the other 
two sequences. Additionally, ZEBRA, but not Fos, was found 
to be phosphorylated by casein kinase II in-vitro. This 
phosphorylation abrogated ZEBRA binding to all of its target 
DNA sequences. Regulation of ZEBRA'S DNA binding activity 
may be required for the progression of the EBV replicative 
cycle.
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CHAPTER I
INTRODUCTION
Epstein-Barr virus (EBV) is a human lymphotropic 
herpesvirus which was first identified in cultured Burkitt's 
lymphoma cells (BL) (Epstein et al., 1964). The virus has 
also been linked to nasopharyngeal carcinoma (NPC), a tumor 
commonly found in southern China (deSchryver et al., 1969). 
Although EBV has not been proven to be the etiologic agent 
in either of these malignancies, it has been shown to 
produce a benign lymphoproliferative disease, infectious 
mononucleosis (Henle et al., 1968, Niedeman et al., 1968). 
This lymphoproliferation can become fatal in patients who 
have inherited or acguired immunodeficiencies (Hanto et al., 
1981, Purtillo, 1981). Additionally, infection with EBV in- 
vitro was found to result in the immortalization of fresh 
neonatal lymphocytes (Henle et al., 1968, Pope et al, 1968, 
Miller et al., 1969).
Lymphoid cells immortalized with the Epstein-Barr virus 
generally maintain the virus in the latent state. These 
cells can harbor up to 800 EBV genomes as unintegrated 
extra-chromosomal plasmids or episomes (Sugden et al.,
1979). The virus is maintained in a tightly latent state in 
both Burkitt's lymphoma and nasopharyngeal carcinoma (Raab- 
Traub et al., 1983, Rowe et al., 1986, Tugwood et al.,
1987). Conversely, EBV was found to be highly replicated in
1
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oral hairy leukoplakia (OHL), an AIDS associated lesion 
(Greenspan et al., 1985). OHL is associated with chronic 
productive EBV infection in the epithelial cells of the 
tongue. In contrast with BL and NPC cells, replicating 
virus and mature EBV virions are found in OHL lesions 
(Greenspan et al., 1985). Thus, Epstein-Barr virus is 
associated with the pathogenesis of disease in both its 
latent and lytic states. This study focuses on the role of 
the EB viral protein, ZEBRA, which regulates the switch 
between the latent and lytic viral life cycles.
The Epstein-Barr viral genome is a double stranded DNA 
molecule of approximately 172,000 base pairs (bp) (Pritchett 
et al., 1975, Hayward and Kieff, 1977, Baer et al., 1984). 
Whereas the EBV genome is linear in virions, it exists as a 
covalently closed circular plasmid in latently infected 
cells (Lindahl et al., 1976, Pritchett et al., 1975). 
Circularization occurs at the terminal repeats; 4-12 direct 
reiterations of a 500 bp sequence (Given et al., 1979, 
Kintner and Sugden, 1979). Only rarely have integrated 
copies of the EBV genome been identified (Henderson et al., 
1983, Matsuo et al., 1984).
EBV infection is restricted to cells expressing the 14 0 
Kd C3d complement receptor which has been designated CR2 or 
CD21 (Fingeroth et al., 1984, Frade et al., 1985). Resting 
B lymphocytes as well as epithelial cells of the orophaynx 
and cervix and some T cell lines express this receptor on
2
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the cell surface (Robinson et al., 1979, Sixbey et al.,
1986, 1987, Stocco et al., 1988). Binding of the virus is 
mediated through the interaction of CR2 and the EBV 
glycoprotein, gp 350 (Hoffman et al., 1980).
EBV infection results in a continuous proliferation of 
lymphocytes in-vitro, a process termed immortalization.
Cells immortalized by EBV maintain the virus in the latent 
state and express only a few virally encoded genes. Ten 
viral gene products have been identified in these cells 
including six EB nuclear antigens (EBNAs, labeled EBNA-1 to 
EBNA-6), the latent membrane protein (LMP), two small RNAs 
(EBER-1 and EBER-2), and the terminal protein (TP) (reviewed 
in Miller, 1990). Although the process of immortalization 
is not well understood, the EBNA-2 protein appears to play a 
critical role. EB viral strains which contain deletions in 
this region (such as P3-HR-1) are immortalization 
incompetent (Bornkamm et al., 1982, Rabson et al., 1982).
Replication of the latent EBV genome in synchrony with 
host cell DNA synthesis results in a stable partitioning of 
the virus to daughter cells (Adams, 1987, Hampar et al.,
1974) . This process requires the interaction of the EBNA-1 
protein with a 1.8 Kb subfragment of the EBV genome termed 
oriP, origin of plasmid replication (Yates et al., 1984). 
EBNA-1 binds a 30 bp repeated sequence located within oriP 
(Rawlins et al., 1985).
Latent EB virus can be activated, in-vitro, by a
3
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variety of external stimuli such as butyrate, phorbol esters 
and serum factors (Bauer et al., 1985, Luka et al., 1979, 
zur Hausen et al., 1979). At least 55 distinct viral genes 
are expressed during the replicative cycle (Hummel and 
Kieff, 1982, Weigel et al., 1983). Early antigens (EA) as 
well as late gene products such as the viral capsid antigen 
(VCA) (a protein sensitive to inhibition of viral DNA 
synthesis) (Summers and Klein, 1976) are expressed following 
induction. Raji cells, which do not replicate viral DNA 
from the lytic origin, can produce early but not late 
antigens (Goodman et al., 1978).
Replicative antigens are spontaneously expressed at a 
low level in some "lytic producer" strains of EBV. The non­
immortalizing HR-1 strain is a lytic virus as defined by its 
ability to induce EA in superinfected latent Raji cells 
(Henle et al., 1970). The HR-1 cell line was derived as a 
subclone of the Burkitt lymphoma cell line, Jijoye (Hinuma 
and Grace, 1967). Restriction analysis of the HR-1 virus 
revealed submolar restriction fragments in addition to the 
standard fragments, suggesting the presence of at least two 
different classes of molecules in these cells (Delius and 
Bornkamm, 1978, Bornkamm et al., 1980). The EBV sequences 
contained within the submolar restriction fragments have . 
been designted 'het', for heterogeneous DNA (Heston et al., 
1982) .
Miller and colleagues subcloned the HR-1 cell line and
4
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recovered two types of clones. The majority of clones 
contained only the standard EBV genome. However, one 
subclone, HR-1 clone 5, contained hypermolar levels of 'het' 
DNA (Rabson et al., 1983). Jenson et al. (1986, 1987) 
demonstrated that het DNA comprises an extensively 
rearranged and deleted HR-1 genome (Fig. 1). The defective 
genome is maintained by cell-to-cell spread and can be lost 
from cell culture (Miller et al., 1985, Kolman, J.L. 
personal communication). HR-1 clone 5 cells spontaneously 
enter viral replication and release a mixture of standard 
and het viruses (Rabson et al., 1983). Additionally, only 
clones harboring het DNA maintain the ability to induce 
early antigen expression in latent EBV (Miller et al.,
1984).
Countryman and Miller (1985) then showed that the 
capacity to activate replication can be mapped to one het 
DNA fragment. The het fragment responsible for disrupting 
latency is a 2700 bp fragment termed WZhet. It represents a 
recombination and inversion of two regions of EBV DNA (BamHI 
W and BamHI Z) which are usually more than 50 Kb apart on 
the standard EBV genome (Fig. 2) (Countryman et al., 1985, 
Jenson and Miller, 1988) . WZhet contains only one complete 
open reading frame, BamHI Z leftward reading frame 1 
(BZLFl), which is inverted relative to its position in the 
standard genome (Fig. 2) (Jenson et al., 1986, Jenson et 
al., 1987). It was not immediately clear whether het DNA
5
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disrupted latency by encoding a novel protein or 
alternatively, that rearrangements in het DNA activated 
expression of a wild type EB viral protein. It has since 
been determined that both the standard and het BZLFl open 
reading frames maintain the ability to disrupt the EBV 
latent cycle (Chevallier-Greco et al., 1986, Countryman et 
al., 1987, Takada et al., 1986). We have termed the protein 
encoded by BZLFl, ZEBRA (Z EB Replication Activator).
Expression and regulation of the ZEBRA protein in the 
standard and HR-1 het EB viruses was analyzed. ZEBRA is 
differentially synthesized in these viruses suggesting that 
the lytic nature of HR-1 is due to an abnormal regulation of 
ZEBRA expression. Additionally, the DNA binding activity of 
ZEBRA was studied. ZEBRA has a broad DNA binding 
specificity which is inhibited by casein kinase II 
phosphorylation. The potential importance of these 
properties in regulating the EBV lytic cycle will be 
discussed.
6
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Figure 1. Physical map of Epstein-Barr viral DNA in one 
cellular subclone of the HR-1 cell line. The boxes 
represent defective (or het) DNA. Boxes with similar 
shading symbolize het DNA sequences which are adjacent to 
each other (from Miller et al., 1984).
Reproduced with permission o f the copyright owner. Further reproduction prohibited w ithout permission.
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Figure 2. Map of WZhet (BamHI het 2.7). The 2.7 Kb WZhet 
fragment is capable of disrupting latency. The fragment 
represents intramolecular recombination and inversion of two 
regions of EBV DNA (BamHI W and BamHI Z) which are more than 
55 Kb apart on the standard EBV genome. All open reading 
frames (horizontal arrows) except BZLFl are truncated (from 
Jenson and Miller, 1988).
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CHAPTER II
EXPRESSION OF THE BZLFl LATENCY-DISRUPTING 
GENE DIFFERS IN STANDARD AND DEFECTIVE 
EPSTEIN-BARR VIRUS
INTRODUCTION
Epstein-Barr virus is maintained in immortal B 
lymphocytes predominantly in the latent state. Expression 
of lytic cycle products occurs spontaneously in a small 
proportion of EBV-infected lymphocytes; however viral 
replication can be induced in many more cells by such agents 
as phorbol esters, butyrate and serum factors (Bauer et al., 
1985, Luka et al., 1979, zur Hausen et al., 1979). Virus 
from the P3HR-1 subline of the Jijoye Burkitt's lymphoma 
also has the capacity to induce EB viral replication (Henle 
et al., 1970, Miller et al., 1984).
The P3HR-1 cell line contains two forms of EBV DNA, a 
standard genome and a defective (heterogeneous or het) 
genome which is extensively deleted and rearranged (Cho et 
al., 1984, Heston et al., 1982). Experiments with cellular 
subclones of the P3HR-1 cell line implicated the het DNA in 
activating replication of the standard EBV genome (Heston et 
al., 1982). HR-1 clone 16 (HH514-16), which is 
representative of the majority of HR-1 subclones, contains 
the standard genome but has lost het DNA and with it the 
capacity to synthesize viral replicative products
11
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spontaneously. HR-1 clone 5 (HH543-5), a rare clone which 
contains hypermolar levels of het DNA as well as standard 
EBV DNA, spontaneously enters viral replication (Rabson et 
al., 1983). Clone 5 cells release a mixture of standard and 
het viruses, the latter of which activate viral replication 
when added to cells bearing a latent genome.
The capacity to activate replication has been mapped to 
the BZLFl open reading frame, which encodes a protein termed 
ZEBRA (Z EB Replication Activator) or EB1 (Chevallier-Greco 
et al., 1986, Countryman and Miller, 1985). ZEBRA is 
responsible for activation of early gene expression 
(Countryman et al., 1987). Whereas the BZLFl open reading 
frame is present in both standard and het genomes, in the 
latter the reading frame is inverted relative to its 
position in the standard genome. In the het genome, BZLFl 
has new upstream and downstream regions as the result of 
intramolecular recombinations (refer to chapter I, Fig. I- 
11) (Jenson et al., 1986, Jenson et al., 1987). This 
altered genome configuration suggests that the BZLFl gene 
might be aberrantly regulated in het DNA.
Previous experiments which characteerized the ability 
of the BZLFl gene product to disrupt viral latency relied 
exclusively on gene transfers of plasmids in which 
expression of the BZLFl gene was driven by strong 
heterologous promoters (Chevallier-Greco et al., 1986, 
Countryman et al., 1987, Hardwick et al., 1988, Takada et
12
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al.f 1986). The purpose of the present experiments was to 
study the pattern of ZEBRA expression during the life cycle 
of standard and defective EB viruses in Burkitt lymphoma 
cells, a natural target.
13
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RESULTS
Properties of the ZEBRA Fusion Protein. A ZEBRA fusion 
protein was obtained by cloning the 679 bp Nael-PvuII 
subfragment of WZhet in frame with the trpE coding sequences 
contained in the pATH 11 vector (Dieckmann and Tzagaloff,
1985). Since a genoomic fragment was used in the expression 
construct, the ZEBRA fusion protein made in bacteria would 
not be identical to that made in eukaryotic cells if 
eukaryotic ZEBRA is expressed exclusively from spliced mRNAs 
(Biggin et al., 1987). The EBV BZLF1 open reading frame 
(ORF) should encode 218 amino acids: 9 amino acids upstream 
of the two methionines at the 5' end of the ORF; 167 amino 
acids from exon 1 of BZLF1 and 42 amino acids downstream 
from the first intron. If the BZLF1 gene is not spliced in 
eukaryotic cells, the 218 amino acid insert included in the 
bacterial fusion protein would encompass the entire 209 
amino acid BZLF1 ORF.
The calculated molecular weight of the protein encoded 
by the EBV insert is 23.3 KDa (Jenson et al., 1988). The 
pATH 11 vector contains sequences coding for a 36 KDa trpE 
polypeptide. The observed electrophoretic mobility of the 
trpE-BZLFl fusion protein, 72 KDa, was about 13 KDa larger 
than calculated. The ZEBRA polypeptide from eukaryotic 
cells also migrates about 13 KDa slower than expected 
(Jenson et al., 1988). The synthesis of fusion protein was 
highly inducible by addition of indoleacrylic acid to HB101
14
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cells transformed with the pATH 11/BZLF1 construct. After 
treatment of the bacterial cell lysate with DNAse I, the 
fusion protein accounted for about 50% of the total protein 
in the insoluble pellet (Fig. 1).
Detection of Polymorphic ZEBRA Polypeptides by Rabbit 
Antisera Raised to the TrpE-BZLFl Fusion Protein. Initial 
experiments evaluated the specificity of the antisera 
obtained from rabbits immunized with the trpE-BZLFl fusion 
protein. Post-immune rabbit sera recognized a nuclear 
antigen in COS-1 cells transfected with pSV2neo-WZhet and in 
HR-1 clone 16 cells treated with TPA (Fig. 2). Preimmune 
rabbit sera did not react with COS-1 cells or HR-1 cells by 
immunofluorescence or by immunoblotting (not shown). The 
post-immunization rabbit sera did not detect antigens in 
untransfected COS-1 cells nor in uninduced clone 16 cells in 
an immunofluorescence assay (not shown).
It was known from immunoblot analysis using polyvalent 
human sera, as well as a weakly reactive rabbit antiserum 
raised to a lac Z-BZLF1 fusion protein, that ZEBRA 
polypeptides from various EBV strains have different 
electrophoretic mobilities (Countryman et al., 1987). By 
means of chimeric mutants and DNA sequence analysis it was 
previously determined that 3 point mutations at amino acid 
positions 25, 51 and 73 in BZLF1 account for the 3 KDa 
difference in electrophoretic mobility of HR-1 het ZEBRA 
(39KDa) and standard HR-1 ZEBRA (36KDa) (Countryman et al.,
15
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1987, Jenson et al., 1988). There is also a reproducible 
difference in electrophoretic mobility of about 1-2 KDa 
between ZEBRA from standard HR-1 and EBV strain FF41. This 
mobility difference disappeared when the proteins were 
further denatured in 8 M urea; however, even after 
denaturation in urea, HR-1 het ZEBRA migrated about 3 KDa 
slower than standard HR-1 ZEBRA (D. A. Katz, unpublished 
data).
The rabbit antiserum to TrpE-BZLFl recognized the 
polymorphic ZEBRA proteins made after transfection of COS-1 
cells with the BZLF1 gene from various EBV strains (Fig. 3). 
Furthermore, using this serum we showed that the ZEBRA 
polypeptide made in lymphoid cells from intact virus 
comigrated with the polypeptide made when the encoding 
region from that virus was transfected into COS-1 cells.
For example, the ZEBRA polypeptide made in butyrate induced 
clone 16 cells co-migrated with ZEBRA expressed in COS-1 
cells transfected with pSV2neo- BamHI Z (HR-1) (Fig. 3). 
Three higher molecular weight bands of 70-90 KDa were also 
detected with antibody to BZLF1 on immunoblots of extracts 
prepared from induced clone 16 cells. These products may 
represent ZEBRA oligomers which were not completely 
denatured prior to electrophoresis.
Kinetics of ZEBRA expression in cells containing only a 
standard EBV genome. The antiserum was used in a time 
course study to determine whether ZEBRA was an early or late
16
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viral protein. ZEBRA could be detected within 6 hrs after 
addition of butyrate to clone 16 cells. Expression reached 
near maximal levels within 2-3 days after addition of 
butyrate and remained elevated throughout a two week period. 
However, cells cultured for 2 weeks in the absence of 
inducing agent failed to express detectable levels of ZEBRA. 
The higher molecular weight immunoreactive proteins were 
first detected about 3 days after butyrate treatment (Fig.
4) .
Additional kinetic experiments were performed in which 
clone 16 cells were induced with butyrate in the presence or 
absence of inhibitors of EBV viral DNA synthesis, 
phosphonoacetic acid (PAA) or acyclovir (ACV). Treatment 
with these inhibitors did not alter ZEBRA expression. The 
higher molecular weight proteins reactive with the antibody 
to BZLF1 were also made in the presence of inhibitors of 
viral DNA synthesis (Fig. 5 and data not shown). The 
efficacy of the inhibitors was monitored by assessing the 
synthesis of a late viral protein, p21. This protein, which 
was induced in clone 16 cells and recognized by the RM 
antiserum 3 and 5 days after induction, was blocked by PAA 
(Fig. 5). When ACV was used, it was found that the drug had 
blocked viral DNA replication. Linear EBV, representing 
replicated genomes, was present following butyrate induction 
only when ACV was absent (Katz et al., 1989). As expected, 
neither ACV nor PAA affected expression of latent products,
17
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EBNAs, recognized by the RM antiserum (Fig. 5). These 
experiments demonstrated that in clone 16 cells ZEBRA was 
not expressed during latency and behaved as an early 
replicative protein following chemical induction. 
Constitutive Expression of ZEBRA in Cells Bearing Both 
Standard and Defective EBV Genomes. It was of interest to 
compare ZEBRA expression in clone 16 cells with its 
expression in spontaneously replicating clone 5 cells. The 
polymorphisms of ZEBRA encoded by WZhet and standard BamHI Z 
(Fig. 3) were used to monitor expression of the two ZEBRA 
variants in clone 5 cells which harbor both standard and 
defective genomes. Clone 5 cells expressed ZEBRA 
spontaneously, without addition of inducing agents (Fig. 6). 
There was generally a lag in ZEBRA expression after 
subculture into fresh medium, but by 2-4 days after 
subculture ZEBRA was detected and persisted thereafter. The 
het variant was predominant and was detected before standard 
ZEBRA.
The effects of two inducing agents, TPA and butyrate, 
were tested in clone 5 cells (Fig. 7). At 3 and 4 days 
after subculture het ZEBRA was made spontaneously, in the 
absence of inducer. In the presence of butyrate, standard 
ZEBRA as well as het ZEBRA, were activated. In many 
experiments (not shown), butyrate preferentially activated 
expression of standard ZEBRA. TPA seemed to induce het 
ZEBRA to a greater extent than standard ZEBRA. These
18
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experiments suggested that there are separate controls on 
expression of ZEBRA from the two genomes.
Since ZEBRA persisted in viral cultures at maximal 
levels for two weeks after induction (Fig. 4), it was of 
interest to determine the stability of the ZEBRA protein. 
Following induction with butyrate, clone 5 cells were 
treated with either cycloheximide or actinomycin D to 
abolish translation or transcription, respectively. As 
expected, the level of ZEBRA protein increased in butyrate 
treated cells during the next 48 hours (Fig. 8). However, 
no decrease in ZEBRA protein was observed in cycloheximide 
or actinomycin D treated cells during the same time period 
(Fig. 8). These results suggest that ZEBRA is a stable 
protein whose half life is greater than 48 hours.
Exogenous Infection with Virus Stocks Containing Both 
Standard and Defective Genomes. Virus stocks prepared from 
clone 5 cells, containing a mixture of standard and 
defective EBV genomes, were inoculated into EBV genome 
negative Burkitt Lymphoma (BL) cells which had been stably 
converted by HR-l (CL16) and B95-8 virus strains (Calender 
et al., 1987, Seibl et al., 1986). The converted lines were 
used as targets in order to compare expression of the 
endogenous standard virus with the superinfecting het and 
standard virus mixture.
All 4 EBV converted BL cell lines maintained the virus 
in a tightly latent state. In these lines, neither TPA nor
19
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butyrate stimulated expression of the ZEBRA from endogenous 
EBV genome (Fig. 9 and data not shown). The same viruses 
(HR-1 clone 16 and B95-8), however, could be induced in 
other cell backgrounds. When the EBV converted cells were 
superinfected by clone 5 virus stocks, het ZEBRA was 
markedly induced by TPA treatment (Fig. 9). Het ZEBRA 
expression in these 4 Burkitt Lymphoma lines was not 
accompanied by synthesis of standard ZEBRA, as it was in 
clone 5 cells. Nonetheless, expression of the het ZEBRA 
protein was associated with the production of a large number 
of early antigens (data not shown).
Transcription of BZLF1 in HR-1 Cells Bearing Standard and 
Defective EBV Genomes. Northern blot analysis was performed 
to determine whether the observed differences in standard 
and het ZEBRA expression were due to regulation at the 
transcriptional level. RNA from clone 16 and clone 5 cells 
was probed with a 523 bp fragment representing 264 bp 
upstream of BZLF and 259 bp of the first coding exon. Two 
prominent mRNAs of 3.5 Kb and 0.9 Kb were detected one and 
two days after butyrate treatment (Fig. 10). In clone 5 
cells the same two mRNAs were expressed spontaneously 
without addition of an inducing agent. In uninduced clone 
16 cells there were no transcripts identified with this 
probe. The experiments indicated that differences in ZEBRA 
expression by clone 16 and clone 5 cells were likely to be 
the result of differences in transcriptional control.
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Northern blots were then probed with fragments specific 
for the BZLF1 and BRLF1 open reading frames in an attempt to 
distinguish between the 3.5 Kb and 0.9 Kb mRNAs. In induced 
clone 16 cells, both mRNAs were recognized by the BZLF1 
specific probe while only the 3.5 Kb mRNA was recognized by 
the BRLF1 specific probe (Fig. 11). These results 
corroborate the finding that the BRLF1 specific mRNA is 
colinear with BZLF1 at the 3' end (Biggin et al., 1987,
Seibl et al., 1987). B95-8 cells, a marmosset EBV line,
expressed a 15 Kb BZLF1 specific transcript in addition to 
the 3.5 Kb and 0.9 Kb transcripts (Fig. 12).
The synthesis of both BZLF1 mRNAs was sensitive to 
treatment with cycloheximide, a protein synthesis inhibitor 
(Fig. 13). Additionally, neither mRNA was detected if 
cycloheximide was added 8 hours following induction of clone 
16 cells with butyrate (Fig. 13).
Kinetics and Stability of BZLF1 specific mRNAs. RNA was
isolated at various time points following TPA induction of 
B95-8 cells in an attempt to determine the kinetics of 
transcription of the BZLF1 specific 3.5 Kb and 0.9 Kb mRNAs. 
Both mRNAs were detected 2 hours after induction and both 
reached maximal levels at 13 hours post induction (Fig. 14). 
The half life of these mRNAs was determined by treating 
butyrate induced clone 5 cells with actinomycin D and 
assessing RNA levels by Northern blot analysis. Again, both 
the 3.5 Kb and 0.9 Kb mRNAs had approximately the same
21
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I
kinetics of expression with a half life of 3.5 hours (Fig. 
15). The half life of these mRNAs is also 3.5 hours in 
clone 16 cells and B95-8 cells (data not shown).
22
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DISCUSSION
Since the BZLF1 gene product can activate the 
expression of many EBV genes in transfection experiments, it 
has been assumed that this gene plays a pivotal role in the 
switch between latency and replication in the context of the 
intact virus (Chevallier-Greco et al., 1986, Countryman and 
Miller, 1985, Hardwick et al., 1988, Seibl et al., 1986). 
However, little is known about the regulation of this gene 
in natural infection. There have been no reports describing 
the effects of different variables on expression of ZEBRA 
protein in lymphoid cells. Regulation of expression of the 
BZLF1 gene differs in cells with or without het DNA and 
these results are summarized in Figure 15. These 
experiments define at least three sets of variables which 
affect ZEBRA expression: presence of defective virus, cell 
background, and addition of chemical inducers such as sodium 
butyrate and TPA.
Defective Virus. The presence of defective virus was 
associated with constitutive ZEBRA expression. The 
defective genomes are easily lost from clone 5 cells (Miller 
et al., 1985). Those clone 5 cells which contain the 
defective virus expressed ZEBRA, while those which have lost 
het DNA no longer synthesize the ZEBRA polypeptide (Kolman, 
J.L., unpublished data). Parental HR-1 cells, which contain 
several different families of defective EBV DNA molecules,
23
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express distinct polypeptides which are reactive with the 
anti-BZLFl serum. Many defective populations activate ZEBRA 
synthesis while the loss of defective virus is usually 
associated with an absence of spontaneous ZEBRA expression 
(J. Kolman, unpublished data).
Seibl et. al. observed a 40 KDa BZLF1 specific protein 
in hybrid-selected translations with RNAs from induced HR-1 
cells. They also immunoprecipitated a 35 KDa BZLF1 protein 
from metabolically labelled cells. Although they concluded 
that the 35 KDa protein was processed from a 40 KDa 
precursor, their studies could not distinguish beween 
expression of products from the standard and defective HR-1 
EBV genomes (Seibl et al., 1986). However, this system 
enabled me to distinguish between the role of standard and 
defective viruses in ZEBRA expression.
The polymorphisms of the ZEBRA polypeptide provided a 
powerful tool with which to assess ZEBRA expression from the 
defective and standard genomes. In the absence of inducers, 
most of the ZEBRA in clone 5 cells was derived from the 
defective genome (Fig. 6,7). When virus stocks containing 
both types of genomes were used to infect EBV converted BL 
cells, het ZEBRA was exclusively expressed (Fig.9). These 
results suggest that aberrant controls on ZEBRA expression 
in the defective genome are responsible for its high level 
of expression. In related experiments using gene transfer 
into BL cells ZEBRA was expressed at high levels from
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plasmids containing the rearranged EcoRI het 16 palindromic 
fragment; ZEBRA was not made when it was introduced on a 
standard BamHI Z fragment (Rooney et al., 1988). Thus, the 
acquisition of new positive regulatory signals as the result 
of the genome rearrangements are likely to explain the high 
level of spontaneous het ZEBRA expression in clone 5 cells.
A fraction of the ZEBRA protein expressed in clone 5 
cells bearing het DNA is derived from the BZLF1 open reading 
frame in the standard genome. This finding suggests that an 
autoregulatory loop may exist; het ZEBRA may activate the 
expression of standard ZEBRA, either directly or by the 
action of other EBV products whose expression is stimulated 
by ZEBRA. The long half life of the ZEBRA may be important 
in its role in regulating the EBV lytic cycle and its 
possible function during the late phase of viral replication 
(Fig. 8).
Cell Background. Cell background provides an important 
influence on ZEBRA expression. Upon de novo infection of 
primary B cells with virus stocks, with or without 
defectives, ZEBRA synthesis is not detected (Rooney et al., 
1989). In EBV converted Burkitt's lymphoma lines there is 
"tight" regulation of ZEBRA expression; inducing agents such 
as TPA or butyrate, are incapable of activating standard 
ZEBRA expression. This may be explained by the recent 
finding that EBV infection of Burkitt's lymphoma lines 
results in the integration of the virus rather than its
25
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maintenance as an extrachromosomal plasmid (Hurley et al., 
1991). Expression may be differentially regulated in 
integrated EBV as compared with an EBV episome.
Preferential expression of het ZEBRA in these cells may 
be due to a gene dosage effect or may be the result of the 
juxtaposition of a TPA responsive element in the het virus. 
Nonetheless, high levels of het ZEBRA expression in a BL 
cell background does not activate expression of standard 
ZEBRA as it does in other cells (Figs. 6 ,7, and 9).
In cell lines in which EBV is less tightly latent, such 
as clone 16 (Fig. 3), Raji, or in vitro EBV immortalized 
cord blood B lymphocytes such as X50-7, ZEBRA is not 
synthesized spontaneously but can be activated with chemical 
inducers and het DNA. The B95-8 and FF41 marmoset cell 
lines, which spontaneously replicate EBV without requirement 
for defective DNA or an inducing chemical, spontaneously 
synthesize ZEBRA. Thus, the tendency of an EBV containing 
cell line to exhibit a tightly latent or a productive 
phenotype correlates with stringent versus loose control on 
ZEBRA expression. This correlation has been strengthened by 
the observation that transfection of a ZEBRA-VP16 fusion 
protein can activate high levels of standard ZEBRA 
expression in clone 16 cells but not in an EBV converted BL 
cell line, BL30/clone 16.(Baumann, Grogan, Gradoville, and 
Miller, manuscript in preparation).
The nature of these host cell-specific controls can
26
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only be conjectured. They may represent positive or 
negative regulatory elements.
Chemical Induction. It seems likely that the pathways by 
which chemicals such as TPA and butyrate activate EBV early 
gene expression intersect with those which control ZEBRA 
gene expression. This hypothesis can be tested since 
inducing agents vary in their effects on cell lines carrying 
different EBV genomes. For example, TPA is a much more 
potent inducing stimulus of early antigen synthesis in Raji 
cells than butyrate and it was found that ZEBRA expression 
is activated to a greater extent in Raji cells by TPA than 
by butyrate (data not shown). However, these experiments 
cannot distinguish which replicative genes are TPA 
inducible.
The inducing drugs differentially affect standard and 
defective EBV. The standard EBV genome in clone 16, is more 
efficiently induced to express ZEBRA by butyrate than by TPA 
(Fig. 7, and data not shown). The defective genome in clone 
5, however, is more strongly affected by TPA. Additionally, 
Rooney et. al. have shown through gene transfers that in the 
genetic environment of het DNA, het ZEBRA expression is 
markedly induced by TPA (Rooney et al., 1988). A probable 
site for the TPA responsive element in the defective DNA is 
the promoter element for the MS-EA gene which is positioned 
downstream of BZLF1 in het DNA. This promoter contains a 
binding site for the AP-1 transcription factor which is TPA
27
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inducible (Angel et al., 1987, Lee et al., 1987). Butyrate 
may activate expression of ZEBRA by altering the nucleosome 
configuration in the cell. Butyrate has been shown to 
inhibit histone deacetylation resulting in histone 
hyperacetylation (Candido et al., 1978, Sealy and Chalkley, 
1978).
However, the differential effects of chemical inducers 
on het versus standard ZEBRA are transient (Fig. 7). A 
likely explanation is that both het and standard ZEBRA 
proteins are each capable of stimulating the other. This 
hypothesis is supported by the finding that spontaneous 
expression of het ZEBRA protein is eventually accompanied by 
expression of the standard ZEBRA protein.
Nature of the control. These experiments indicate that the 
major controls on ZEBRA expression are at the 
transcriptional level. Chemical induction of cells 
containing only standard virus such as clone 16, Raji and 
B95-8 is invariably associated with marked increases in 
BZLF1 mRNA (Figs. 9, 11, 13, and data not shown). However, 
in clone 5 cells which contain a defective virus, BZLF1 
specific transcripts are made constitutively and are not 
always increased by butyrate treatment. The level of ZEBRA 
mRNAs in these cells varies with culture conditions such as 
temperature, cell density, and interval since feeding (not 
shown). These variables probably reflect cellular controls 
on the het virus.
28
Reproduced with permission o f the copyright owner. Further reproduction prohibited w ithout permission.
Since this work was completed, Manet et al. reported 
the isolation of four BZLF1 specific cDNAs clones: a spliced 
BZLF1 with three exons; two bicistronic BRLF1-BZLF1 clones, 
encoding an unspliced BRLF1 ORF and the spliced BZLF1 gene; 
and a spliced BZLF1 clone with a deleted 5' terminus (Manet 
et al. 1989). In these experiments, only two BZLF1 specific 
mRNAs were detected in a number of EBV positive cell lines; 
corresponding to the spliced BZLF1 mRNA and one bicistronic 
BRLF1-BZLF1 message (Figs. 10, 11, 12). However, the 0.9 Kb 
message is generally of higher abundance than the 3.5 Kb 
transcript and may represent more than one BZLF1 transcript. 
Additionally, a 15 Kb BZLF1 specific message was detected in 
induced B95-8 cells (Fig. 12). This message may correspond 
to the leftward transcript hybridizing to BamHI-W previously 
described by Rogers and Speck (1990). Thus, the message 
encoding the entire ZEBRA protein is contained within at 
least three transcripts. However, it has still not been 
determined whether ZEBRA is translated from all these mRNAs 
in-vivo.
Studies of the kinetics of expression of the 3.5 and 
0.9 Kb messages suggest that they may be regulated by 
similar cellular controls. Both messages were detected 
within two hours following induction (Fig. 14) and both have 
a half life of approximately 3.5 hours (Fig. 15).
These results help clarify previously published results 
on BamHI Z transcripts. Biggin et. al. detected two
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transcripts of 2.8 Kb and 1.0 Kb from BRLF1 and BZLF1, 
respectively, in HR-1 superinfected Raji cells treated with 
protein synthesis inhibitors and suggested that these 
"immediate early" transcripts are derived from the defective 
genome (Biggin et al., 1987). However, under the conditions 
of their experiment, they could not ascertain whether the 
transcripts were expressed from the Raji genome, the HR-1 
standard genome, or the HR-1 defective genome.
Laux et al. showed that these two transcripts could be 
detected in the defective Raji cell line after induction 
with TPA (Laux et al., 1988). However, in contrast to 
transcripts made after superinfection, those induced by TPA 
were not detected in the presence of a protein synthesis 
inhibitor, cycloheximide. They suggested that the mechanism 
of activation of replication by superinfection and by TPA 
are different (Laux et al., 1988).
These experiments support the findings of Laux et al. 
since synthesis of both the 3.5 Kb and 0.9 Kb BZLF1 specific 
mRNAs in clone 16 cells were sensitive to inhibition of 
protein synthesis with cycloheximide (Fig. 13). Therefore, 
a viral, or possibly cellular protein must be made before 
ZEBRA mRNA can be synthesized in cells with a standard 
unrearranged genome. Additionally, de novo protein 
synthesis may be continually required for BZLF1 
transcription from standard virus since no ZEBRA specific 
transcripts were detected in cells which were treated with
30
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cycloheximide 8 hours following addition of butyrate (Fig. 
13). Although BZLF1 transcripts are not detected in any of 
the cycloheximide + butyrate treated cells, RNA extracts 
from these cells, but not from uninduced cells, consistently 
demonstrate a high level of background hybridization with 
BZLF1 specific probes. This suggets that de-novo protein 
synthesis may be required for the stabilization of BZLF1 
transcripts. However, in cells containing a defective 
virus, transcripts are made constitutively and do not appear 
to require new protein synthesis.
Future work will entail a search for differences in the 
control mechanisms on BZLF1 in the standard and defective 
viruses. Control may involve repressors encoded by the 
virus or the cell as well as transcription factors which are 
activated by inducing agents.
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Figure 1. Appearance of the TrpE BZLF1 fusion protein on a 
polyacrylamide gel stained with Coomassie brilliant blue.
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Figure 2. Reactivity of rabbit antiserum to the TrpE-BZLFl 
fusion protein by immunofluorescence. COS-1 cells were 
transfected 3 days previously with pSV2neo/WZhet. HR-1 
clone 16 cells were treated with TPA for 3 days. The rabbit 
antiserum was used at a 1:30 dilution; rhodamine conjugated 
anti-rabbit Ig at 1:50.
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ANTISERUM: ANTI BZLFI
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Figure 3. Reactivity of rabbit antiserum to the TrpE-BZLFl
fusion protein by immunoblottina. Extracts were prepared 
from HR-1 clone 16 cells which were untreated (C16) or 
treated with butyrate for 3 days (C16+B). COS-1 cells were 
transfected with pSV2neo plasmids containing WZhet, the 
BamHI Z fragment from EBV strains FF41, HR-1, or no insert. 
The immunoblot was probed with a 1:100 dilution of rabbit 
antiserum to BZLFI.
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Figure 4. Kinetics of ZEBRA expression after butvrate 
induction of HR-1 clone 16 cells. Each time point 
represents an extract of 2 X 106 cells which was 
electrophoresed through a 10% SDS-polyacrylamide gel. The 
immunoblot was probed with rabbit antiserum to the 
TrpE-BZLFl fusion and I - protein A.
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Figure 5. Lack of effect of phosohonoacetic acid fPAAt on 
ZEBRA expression in HR-1 clone 16 cells. Cells were 
uninduced or induced with butyrate. An aliquot of induced 
cells was also treated with PAA. Cell extracts were 
analyzed after 3 or 5 days on duplicate immunoblots with 
rabbit anti-BZLFl serum or polyvalent human antiserum, RM, 
which recognizes a p21 late protein. ZEBRA expression is 
unaffected by PAA but p21 synthesis is inhibited.
40




+• m  
i m 







4- ro  
I ro  










Reproduced with permission o f the copyright owner. Further reproduction prohibited w ithout permission.
Figure 6. Constitutive Expression of ZEBRA, in HR-1 clone 5 
cells. Duplicate experiments are illustrated. Extracts 
were prepared at intervals after splitting the cells at a 
ratio of 1:4 (left) or 1:5 (right). There is a delay in 
ZEBRA expression after the cells are split. Beginning at 
2-4 days after subculture ZEBRA is expressed spontaneously, 
without addition of an inducing agent. The het variant is 
more abundant than standard ZEBRA.
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Figure 7. Effects of inducing agents on expression of the 
two ZEBRA variants in HR-1 clone 5 cells. Uninduced cells 
express mainly the het variant; after addition of TPA or 
butyrate both the het and standard ZEBRAs are expressed. 
TPA has a greater effect on het ZEBRA whereas butyrate 
preferentially stimulates the standard variant.
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Figure 8. Stability of the ZEBRA protein. Clone 5 cells 
were induced for three days with butyrate at which time 
transcription or protein synthesis were inhibited with 
actinomycin D or cycloheximide, respectively. Cells were 
then harvested at various time points following inhibition. 
Each time point represents an extract of 1 X 106 cells which 
were electrophoresed through a 10% SDS-polyacrylamide gel. 
The immunoblot was probed with rabbit anti-BZLFl serum.
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Figure 9. Expression of ZEBRA after infection of Burkitt 
lymphoma cell lines BL30 and BL2 stably converted with the 
B95-8 and HR-1 clone 16 strains of EBV. The cells were 
treated (+) or untreated (-) with TPA and infected (+) or 
uninfected (-) with clone 5 virus stocks. Western blots 
prepared 48 hrs after infection were reacted with anti-BZLFl 
serum. Following infection of converted BL30 or BL2 cells 
the het ZEBRA is expressed in the presence of TPA. However, 
in these cells, the standard ZEBRA from clone 16 or B95-8 
virus is not expressed after TPA induction or 
superinfection with clone 5.
48
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Figure 10. Northern blot analysis of BZLF1 transcription in 
HR-1 clone 16 and clone 5 cells. RNA was prepared from 
uninduced clone 16 cells 1 day after subculture and from 
butyrate treated clone 16 cells at one and two days after 
subculture. RNA was prepared from clone 5 cells two days 
after subculture in the absence or presence of butyrate.
Both blots were probed with a 523 bp subfragment of mutant 
80 of WZhet (Countryman et al., 1987). The filter 
containing clone 16 RNAs was stained with methylene blue to 
demonstrate that the level of ribosomal RNAs from the 
uninduced and induced cells was similar.
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Figure 11. Localization of BZLF1 specific transcripts. RNA 
was prepared from uninduced and butyrate treated clone 16 
cells one day after induction. RNAs were electrophoresed in 
duplicate and Northern blots were probed with a 395 bp BZLF1 
specific fragment or a 538 bp BRLF1 specific fragment. Both 
the 3.5 Kb and 0.9 Kb mRNAs are detected with the BZLF1 
probe whereas only the 3.5 Kb mRNA is detected with the 
BRLF1 specific probe.
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Figure 12. Northern blot analysis of BZLF1 transcription in
B95-8 cells. RNA was prepared from uninduced and TPA 
treated B95-8 cells. The blot was probed with a 627 bp 
subfragment of BZLF1. A 15 Kb mRNA is detected in addition 
to the 3.5 Kb and 0.9 Kb BZLF1 specific mRNAs.
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Figure 13. Protein synthesis is required for BZLF1 
transcription following butvrate induction. Clone 16 cells, 
which contain only standard EBV DNA, were untreated or 
induced with butyrate. A) An aliquot of the butyrate 
treated cells was treated with the protein synthesis 
inhibitor, cycloheximide. After 24 hours RNA was harvested 
from the three groups of cells and probed on a Northern blot 
with a 627 bp subfragment of BZLF1. The two BZLF1 specific 
mRNAs, 3.5 Kb and 0.9 Kb, are detected in butyrate treated 
cells but are not expressed in the presence of 
cycloheximide. B) Cycloheximide was also added to different 
cell aliquots at 1, 2, 4, and 8 hours following butyrate 
induction. RNA was harvested 48 hours after induction and 
similarly probed on a Northern blot with the BZLF1 
subfragment. The BZLF1 specific mRNAs were not detected in 
any of the cyloheximide treated cells.
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Figure 14. Kinetics of BZLF1 transcription in TPA induced 
B95-8 cells. Each time point represents RNA harvested from 
1 X 106 cells. The Northern blot was probed with the 627 bp 
BZLF1 subfragment. The 3.5 Kb and 0.9 Kb BZLF1 specific 
mRNAs are detected simultaneously.
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Figure 15. Stability of BZLF1 specific mRNAs in butyrate 
induced clone 5 cells. Clone 5 cells were induced with 
butyrate for 2 days prior to inhibition of transcription 
with actinomycin D. RNA was harvested at various time 
points. Each time point represents RNA from 1 X 106 cells 
and the blot was probed with the 627 bp BZLF1 subfragment. 
The 3.5 Kb and 0.9 Kb BZLF1 specific mRNAs have similar 
stabilities.
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Figure 16. Differences in regulation of BZLF1 expression in 
HR-1 cells with or without het DNA. Clone 16 cells, which 
lack het DNA, express latent products (shaded nuclei) and 
spontaneously enter the replicative cycle at a low rate 
(0.1% of cells). Clone 5 cells, which harbor het DNA, 
spontaneously produce virus. BZLF1 expression was studied 
in untreated cells or after induction with TPA or butyrate. 
BZLF1 specific transcripts were detected by Northern 
blotting and ZEBRA protein expression was assayed by Western 
blotting with a monospecific antiserum (from Miller, 1990).
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DNA BINDING ACTIVITY OP ZEBRA: THE EPSTEIN-BARR 
VIRAL REPLICATION ACTIVATOR
INTRODUCTION
Epstein-Barr virus infection of lymhoid cells, either 
in-vitro or in-vivo, results in lymphocyte immortalization 
and viral latency (reviewed Miller, 1990a). Several groups 
have now shown that expression of the EB viral gene, BZLF1 
results in a switch to the lytic viral life cycle 
(Countryman and Miller, 1985, Chevallier-Greco et al, 1986, 
Takada et al., 1986). The mechanism by which the BZLF1 gene 
product, ZEBRA, activates the replicative cycle has not yet 
been determined.
Recently, Farrell and co-workers determined that exon 
II of ZEBRA shares homology with the basic domain of the 
Fos/Jun oncogene family (Fig. 1) (Farrell et al., 1989). 
Fos/Jun related proteins have previously been shown to bind 
the canonical AP-1 site (TGAGTCA), and Farrell et al. (1989) 
showed that ZEBRA bound an AP-1 consensus sequence located 
in the promoter of an EBV early gene, MS-EA (Angel et al., 
1987, Lee et al., 1987, Hope and Struhl, 1987, Farrell et 
al., 1989). All of the Fos/Jun related proteins require 
dimerization for DNA binding and have been shown to dimerize 
through a leucine zipper motif, a region containing leucines 
at heptad intervals (Abel and Maniatis, 1989, Agre et al.,
64
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1989, Gentz et al., 1989, Kouzarides and Ziff, 1988, 1989, 
Landschulz et al., 1988, Neuberg et al., 1989a, Sassone- 
Corsi et al., 1988, Schuerman et al., 1989, Sellers and 
Struhl, 1989, Vinson et al., 1989). ZEBRA, however, does not 
contain a leucine zipper dimerization domain downstream of 
its basic domain. Additionally, ZEBRA has been shown to 
bind to sites which deviate from the AP-1 consensus sequence 
(Chang et al., 1990, Flemington and Speck, 1990b, Lieberman 
and Berk, 1990, Packham et al., 1990, Taylor et al., 1991a, 
Urier et al., 1989). Thus, it was of interest to define the 
domains of the ZEBRA protein required for DNA binding and 
determine whether ZEBRA binds DNA as a dimer.
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RESULTS
Determination of the ZEBRA DNA Binding Domain by Deletional 
Mutagenesis. A BZLF1 cDNA obtained from Ra j i cells was 
cloned in frame with the trpE coding sequences contained in 
the pATH 11 expression vector (Fig. 2B). The 75 kilodalton 
(Kd) fusion protein bound a 20 base pair (bp) 
oligonucleotide which contains an AP-1 consensus sequence 
(MS-AP-1) derived from the promoter of the EBV early gene, 
MS-EA (Figs. 2C, 2D, Z1_245) . Several deletion mutants 
defined the domain of the protein which bound the AP-1 site 
(Figs. 2C, 2D). All of the mutants exhibited some 
temperature sensitive DNA binding activity. Mutant ZU1_245 
encoded the smallest protein which behaved like the wild 
type ZEBRA (Z1_2A5) in binding DNA both at room temperature 
and at 4C (Fig. 2A). However, even this mutant did not bind 
DNA as well at 4C as the wild type Z.|_245. The region of 
ZEBRA encoded by exon II, which shares homology with the Fos 
basic domain (Farrell et al., 1989), was insufficient to 
elicit DNA binding activity (Fig. 2C, 2D, Z16a_202) . Although 
Z 11i_159 bound DNA unstably (see smear, Fig. 2C) at room 
temperature (22°C) and Z172_245 did not bind DNA under these 
conditions (Fig. 2C), both mutant proteins bound DNA at 4°C 
(Fig. 2D). Deletion of the 18 carboxyl amino acids of ZEBRA 
resulted in a mutant (ZV227) which bound the AP-1 site at 
room temperature, but not at 4°C (Figs. 2C, 2D) .
Furthermore, all the ZEBRA deletion mutants showed the same
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pattern of binding to the divergent AP-1 sites, ZIIIA and 
ZIIIB, present in the BZLF1 promoter (data not shown, refer 
to chapter IV). Thus, ZEBRA amino acids 172-227 are 
required for DNA binding although neighboring sequences may 
influence protein folding or stability under some 
temperature conditions.
General DNA Binding Activity of ZEBRA mutants. DNA binding 
of ZEBRA mutants was also analyzed by the ability of ZEBRA 
proteins to bind an array of DNA sequences. Z,.^ as well as 
the unspliced ZEBRA protein from rearranged het DNA, WZ.,. 
167(+41) (which contains 167 amino acids from the first exon of 
Zhet plus 41 amino acids from the first intron), were 
electrophoresed in an SDS-polyacrylamide gel, blotted onto 
nitrocellulose and incubated with radiolabeled pSV2neoWZhet 
DNA. Suprisingly, both proteins bound DNA, and the 
unspliced Zhet protein appeared to have a greater intrinsic 
DNA binding potential than the wild type ZEBRA protein,
(Fig. 3A). Whereas pSV2neoWZhet contains an AP-1 binding 
site, identical results were obtained when the proteins were 
incubated with radiolabeled pATH vector DNA (data not 
shown). In an attempt to determine whether a bacterial 
protein, or TrpE, which is present at the 5' terminus of the 
ZEBRA constructs is affecting DNA binding, the DNA binding 
of bacterial extracts as well as TrpE was analyzed.
Bacterial extracts, cells transformed with the trpE vector 
as well as TrpE- WZ.,_167(+41) were electrophoresed and stained
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with Coomassie brilliant blue (Fig. 3B). An identical gel 
was transferred to nitrocellulose and probed with pSV2neo 
WZhet. While several low molecular weight bacterial bands 
were observed in all lanes, TrpE did not bind DNA and TrpE- 
Wzi-167(+41) a<?a;*-n bound DNA strongly (Fig. 3C) .
The location of this general DNA binding domain was 
mapped by deletional mutagenesis of TrpE- 
Construction of the deletions is described in the 
Experimental Procedures and the extent of the deletions is 
shown in Fig. 4A. All deletion proteins were stably 
expressed as assayed by coomassie blue staining of an SDS- 
polyacrylamide gel (data not shown). The results of the 
general DNA binding assay indicated that the smallest clone 
capable of binding DNA was WZ133_167(+41) (Fig. 4B) . 
Interestingly, WZ133_167(+4) did not bind DNA suggesting that 
intron sequences from WZhet were important for the general 
DNA binding ability of this protein (Fig. 4B). A clone 
containing only the basic domain of the ZEBRA protein 
encloded by exon II, Z168_202(+4), was not able to bind DNA in 
this assay (data not shown).
Site Directed Mutagenesis of the ZEBRA Basic Domain. The
region of ZEBRA encoded by the second exon of BZLF1 (aa 168- 
2 02) is partially homologous to the basic region of Fos 
(Fig. 1, 5A). It has recently been shown that amino acids 
144-146 and 154-156 are required for the DNA binding ability 
of Fos (Neuberg et al.,1989b). These basic amino acids are
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conserved at positions 178-180 and 188-190 of ZEBRA exon II. 
Whereas ZEBRA exon II sequences were not necessary for the 
general DNA binding of the protein, they were necessary for 
binding to the AP-1 heptamer (Figs. 2 and 4). Therefore, we 
were interested in determining whether the same basic amino 
acids contribute to the specific DNA binding activity of 
ZEBRA. The ZEBRA residues were mutated from lys-arg-tyr to 
glu-glu-leu and arg-lys-cys to glu-glu-ser, respectively 
(Fig. 5A, courtesy E. Flemington). These mutations 
abrogated DNA binding to the consensus (MS-AP-1) as well as 
divergent AP-1 sites (ZIIIA and ZIIIB) (Fig. 5B, courtesy E. 
Flemington). Equivalent amounts of the in vitro translated 
wild type and mutant proteins were used in each reaction 
(data not shown). These results demonstrate that the same 
basic residues in ZEBRA and Fos are required for binding to 
AP-1 and related sequences. However, deletional mutagenesis 
showed that these basic residues are necessary but not 
sufficient for sequence specific DNA binding (Fig. 2).
ZEBRA Binds DNA as a Stable Homodimer. Proteins which bind 
palindromic DNA binding sites have generally been shown to 
bind DNA as a dimer, where each protein binds the dyad half 
site (reviewed in Johnson and McKnight, 1989). Since ZEBRA 
binds a consensus sequence with two dyad half sites 
(TGAGTCA) and contains homology to the Fos/Jun dimeric 
proteins (Abate et al., 1990, Farrell et al., 1989, Hope and 
Struhl, 1987, Kouzardies and Ziff, 1988, Landschulz et al.,
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1988, Sassone-Corsi et al., 1988), the hypothesis that ZEBRA 
also binds DNA as a homodimer was tested.
The method used by Hope and Struhl (1987) to show that 
the GCN4 protein bound DNA as a dimeric protein was 
utilized. When proteins are complexed to DNA on an 
acrylamide gel, the mobility of the complex is proportional 
to the molecular weight of the protein. When Z.,_245 was 
analyzed by gel retardation analysis its mobility was less 
than that of the truncated ZEBRA binding protein, Z141_245 
(Figs. 2 and 6). In order to determine whether ZEBRA bound 
DNA as a homodimer, a protein lysate containing Z1.245 and 
z141-245 were denatured together in 6M urea and then renatured 
prior to analysis by gel mobility. A shifted complex of 
intermediate mobility, in addition to the two complexes 
observed when either of these proteins bound DNA separately, 
was observed (Fig. 6, lane (Z1_2A5 + Z141_245)u) . The detection 
of an intermediate sized band suggests that this complex is 
composed of a heterodimer of the individual proteins.
This method has been successfully used to show that the 
bovine papilloma virus E2 protein and yeast transcriptinal 
activator bind DNA as a dimer and trimer, respectively 
(Dostatni et al., 1988, Giri and Yaniv, 1988, McBride et 
al., 1989, Sorger and Nelson, 1989). Furthermore, no 
heterodimer complex was formed if the ZEBRA proteins were 
mixed following renaturation; indicating that complex 
association occurs immediately after dissociation and is
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I
stable in the absence of DNA (Fig. 6, lane + (Z141_
245)u) •
71
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DISCUSSION
A Comparison of ZEBRA and Fos DNA Binding Domains. The
construction and expresssion of ZEBRA deletion mutants in E. 
coli enabled a determination of the domains within the ZEBRA 
protein which are required for DNA binding. These studies 
indicate that the region 3' to the ZEBRA basic domain (aa 
199-227) is required for DNA binding. The carboxy-terminal 
18 amino acids (228-245), while not strictly required for 
DNA binding, may also contribute to dimer formation and/or 
protein stability since mutants lacking this region bind DNA 
in a temperature sensitive fashion (Figs. 2C and 2D). These 
results are consistent with those of Packham et al. who 
found that mutants which deleted the same regions of exon 1 
or 3 bound DNA in a salt dependent manner, whereas the wild 
type protein bound DNA under all conditions (Packham et al., 
1990).
Site directed mutagenesis of c-fos previously 
identified the amino acids necessary for DNA recognition of 
the Fos/Jun complex (Neuberg et al., 1989b). Mutagenesis of 
Fos amino acids 144-146 or 154-156 completely abrogated DNA 
binding (Neuberg et al., 1989b). The corresponding amino 
acids are conserved in the basic domain of ZEBRA exon II and 
proteins mutated in these positions were unable to bind any 
of the DNA binding sites (MA-AP-1, ZIIIA, or ZIIIB) (Fig.
5). These results suggest that while the DNA binding 
specificities of Fos and ZEBRA differ, the same two clusters
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of basic amino acids are necessary for the specific DNA 
binding ability of both proteins. Further work is needed to 
define the amino acids in the basic region which confer the 
unique binding specificities of Fos and ZEBRA (refer to 
chapter IV).
General DNA Binding of the ZEBRA Protein. The region 
responsible for the ability of the unspliced het ZEBRA 
protein to bind DNA in a nitrocellulose filter binding assay 
has been localized to the 35 carboxy-terminus amino acids in 
exon I (aa 133-167) and the 41 amino acids present in the 
first intron (Fig 4). The residues within the carboxy 
terminus as well as the intron are highly basic, a 
characteristic of many DNA binding domains. It is not clear 
whether het ZEBRA is ever expressed in-vivo in this 
unspliced form, but a cDNA corresponding to the unspliced 
standard ZEBRA has never been detected (Biggin et al., 1987, 
Manet et al., 1989).
This filter binding method has previously been used to 
map the intrinsic DNA binding domains of the v-myb and c-myc 
proteins (Klempnauer and Sippel, 1987, Dang et al., 1989). 
The intrinsic DNA binding domain of v-myb has also been 
shown to confer sequence specific DNA binding potential 
(Klempnauer and Sipper, 1987, Biedenkapp et al., 1988, 
reviewed in Luscher and Eisenman, 1990b). However, the 
region of c-myc necessary for its nonspecific DNA binding 
does not include the basic, helix-loop-helix and leucine
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zipper domains of the protein which were required for its 
sequence-specific DNA binding potential (Blackwood and 
Eisenman, 1991, Blackwell et al., 1990, Dang et al., 1989, 
Prendergast and Ziff, 1989, reviewed in Luscher et al., 
1990a). Thus, the importance of nonspecific DNA binding 
domains in both c-myc and ZEBRA has yet to be determined. 
Function of ZEBRA Exon III. Unlike all other identified 
transcription factors which bind the AP-1 consensus 
sequence, ZEBRA does not contain a leucine zipper directly 
adjacent to the basic region (Landschulz et al., 1988,
Vinson et al., 1989). While ZEBRA exon III (aa 199-245) is 
not homologous to any known dimerization domain (Vinson et 
al., 1989), ZEBRA binds DNA as a homodimer (Fig. 6) and this 
region is required for specific binding (Figs. 2C and D).
It has been hypothesized that this domain forms an alpha 
helix and that dimerization involves a coiled coil 
interaction (Flemington and Speck, 1990c, Kolman et al., 
1991, Lieberman and Berk, 1990, Packham et al., 1990, Taylor 
et al., 1991a). Moreover, O'Shea and colleagues (1989) have 
hypothesized that the leucine zipper motif forms a coiled 
coil structure and have recently shown that the x-ray 
structure of the leucine zipper is a coiled coil (Rasmussen 
et al., 1991). Both ZEBRA exon III and the leucine zipper 
domain contain the 4-3 hydrophobic repeat necessary for 
generation of a coiled coil structure (O'Shea et al., 1989, 
Flemington and Speck, 1990c).
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The existence of different leucine zipper and coiled 
coil motifs is important in regulating DNA binding of 
various proteins. ZEBRA, as well as the Fos and Jun 
protooncogenes and the yeast regulatory protein, GCN4 all 
bind the TPA response element (AP-1, TGAGTCA). However, the 
dimerization potentials of these proteins are very specific. 
A GCN4 leucine zipper homodimerizes whereas a Fos zipper 
dimerizes specifically with Jun and Jun dimerizes with 
itself and Fos (Kouzarides and Ziff, 1989, Neuberg et al., 
1989a, Sellers and Struhl, 1989, Nakabeppu and Nathans,
1989) . While ZEBRA has the potential to bind DNA as a 
homodimer, heterodimerization with a leucine zipper protein 
or a yet unidentified protein may be important for the 
induction of cellular genes and/or the negative regulation 
of ZEBRA responsive genes.
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Figure 1. Homology among basic DNA binding domains of BZLF1
and the AP-1 family of proteins. Data are derived from 
Farrell et al. (1989). Positions of the various amino acids 
are as follows: BZLF1, amino acids 175-196; cFos,140-161; 
cJun, 264-285; and GCN4, 228-249. Most of the homology 
consists of positively charged residues (arginines, R and 
lysines, K) (from Miller, 1990b).
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Homology among DNA Binding Domains
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R R RC RLERConsensus: R-RN -AA- R-R
K K KS KRQL
Figure 2. DNA binding activity of ZEBRA mutants. (A)
Structure of ZEBRA deletion mutants. The ZEBRA cDNA is 
shown at the top (Manet et al., 1989) and clones are 
designated according to the ZEBRA amino acids present in the 
construct. ZA111_159 is named according to the amino acids 
which have been deleted. Z,.167 was derived from genomic 
WZhet DNA (Taylor et al., 1989). Translated sequences which 
are derived from ZEBRA intron sequences are indicated by a 
hatched bar and sequences from the expression plasmid 
polylinker are indicated by a stippled bar. (B) Expression 
of TrpE-ZEBRA fusion proteins in bacteria. Total protein 
from bacteria which carried various TrpE-ZEBRA deletion 
proteins was resolved by SDS-polyacrylamide gel 
electrophoresis and stained with Coomassie brilliant blue. 
The fusion protein is indicated with dots in each lane. (C) 
Gel retardation assay showing binding of TrpE-ZEBRA deletion 
mutants to a 20 bp 32P-labeled oligonucleotide containing 
the AP-1 consensus sequence (Farrell et al., 1989). Extract 
from bacteria transformed with the trpE plasmid, pATH 11, 
was used as a negative control (vector lane). Binding 
reactions and electrophoresis were performed at room 
temperature (RT,22C). Complexes were electrophoresed on a 
4% acrylamide gel in 0.5X TBE. (D) Gel retardation assay of
the same TrpE-ZEBRA deletion mutants performed as in (C) 
except that binding reactions and electrophoresis were 
carried out at 4C.
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Figure 3. Non-specific DNA binding of ZEBRA proteins. (A)
Z.|_245 and WZ.|_167(+41) were electrophoresed on a 10% SDS- 
polyacrylamide gel and blotted onto nitrocellulose. The 
blot was then incubated with 32P-labeled PSV2neoWZhet and 
analyzed by autoradiography. (B) Protein extracts from E. 
coli AG1 cells, AG1 cells transformed with the trpE pATH 
expression vector, and cells transformed with trpE-WZ1 
were analyzed by Coomassie brilliant blue staining of an 
SDS-polyacrylamide gel. (C) An identical gel was 
transferrred to nitrocellulose and analyzed by 
autoradiography following incubation with 32P-labeled 
PSV2neoWZhet. Identical results were obtained following 
incubation with 32P-labeled pATH vector DNA (data not 
shown).
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Probe: pSV2neo WZhet Coomassie blue 
stain
pSV2neo WZhet
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Figure 4• Mapping the non-specific DNA binding domain of 
^ 1-167(+4D* Structure of WZ deletion mutants. The
structure of WZhet is shown at the top; a bar indicates an 
exon and a line denotes an intron (Jenson et al., 1988). 
Clones are designated according to the WZhet amino acids 
present in the construct. Amino acids denoted in parentheses 
refer to those amino acids which are translated from intron 
sequences. (B) Proteins extracts were prepared from induced 
AG-1 cells harboring trpE expression plasmids containing
^ 1-167(+41) ' ^ 1-88' ^ 133-167(+41)' an<̂  ^ 133-167(+4) * Extracts Were 
electrophoresed on an SDS-polyacrylamide gel and then 
transferred to nitrocellulose. The blot was probed with 
32P-nick translated PSV2neoWZhet and analyzed by 
autorad i ography.
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Figure 5. Effect of point mutations in the basic domain of 
ZEBRA. (A) Amino acid sequences of human c-fos exon III (aa 
132-167) (van Straaten et al., 1983) and BZLF1 exon II (aa 
168-202) (Biggin et al., 1987). The conserved residues in 
this highly basic domain are indicated by lines (Farrell et 
al., 1989). ZEBRA mutants were obtained by site directed 
mutagenesis of the BZLF1 cDNA cloned in SP64. Amino acids 
178-180 and 187-189 were changed as shown for Z-M178-80 and 
Z-M187-89, respectively. (B) Gel retardation assay 
demonstrating the inability of ZEBRA constructs mutated at 
aa 178-180 (Z-M178-80) or 187-189 (Z-M187-89) to bind MS-AP- 
1, ZIIIA, or ZIIIB. The wild type (Z-WT) and mutated ZEBRA 
constructs (Z-M178-180 and Z-M187-189) were transcribed in- 
vitro with SP6 polymerase and translated in a wheat germ 
extract. Equivalent amounts of the resulting translated 
proteins were each incubated with the following 32P-labeled 
oligonucleotide probes: MS-AP-1, ZIIIA, and ZIIIB (see 
Experimental procedures for a listing of these sequences). 
These complexes were then resolved by gel electrophoresis on 
a 4% acrylamide gel in 0.5X TBE.
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Figure 6 . ZEBRA binds DNA as a stable homodimer. Z1-245 anĉ  
zui-245 were dissociated with urea and then reassociated 
either separately (Z^jU + Z141_245u) or together ((Z1_24S + Z14l_ 
245)u) prior to gel retardation analysis. Proteins were used 
in a gel binding assay with the 20 bp 32P-labeled 
oligonucleotide containing the AP-1 consensus sequence.
The various protein extracts were incubated with the 
oligonucleotide probe and 1 ug poly dldC in binding buffer 
for thirty minutes prior to electrophoresis. Binding 
reactions and electrophoresis were performed at room 
temperature (RT,22C) and complexes were electrophoresed on a 
4% acrylamide gel in 0.5X TBE.
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CHAPTER IV
ZEBRA AND FOS DIFFER IN THEIR DNA BINDING 
SPECIFICITIES FOR SITES IN THE 
EPSTEIN-BARR VIRAL BZLF1 PROMOTER
INTRODUCTION
Epstein Barr Virus (EBV) persists in lymphoid cells in 
a latent state but can be activated in vitro by phorbol 
esters, butyrate or expression of a virally encoded gene, 
ZEBRA (Chevallier-Greco et al., 1986, Countryman et al., 
1985, Gradoville et al., 1990, Luka et al., 1979, Taylor et 
al., 1989, van Straaten et al., 1983). The mechanism by 
which ZEBRA initiates the cascade of viral replication has 
been the focus of much study. Numerous groups have found 
that ZEBRA directly transactivates several promoters of 
lytic cycle genes, including a region integral to the EBV 
lytic origin of replication (Chavrier et al., 1989, 
Chevallier-Greco et al., 1986, Flemington et al., 1990, 
Gradoville et al., 1990, Hammerschmidt et al., 1988,
Hardwick et al., 1988, Kenney et al., 1989, Lieberman et 
al., 1990, Urier et al., 1989).
Exon II of ZEBRA is homologous to the basic domain of 
the Fos/Jun proto-oncogene family (Farrell et al., 1989).
In Fos/Jun complexes, this domain has been shown to interact 
directly with a DNA heptamer known as the TRE or AP-1 site
89
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(TGAGTCA) (Angel et al., 1987, Lee et al., 1987, Neuberg et 
al., 1989b). It was determined that ZEBRA shares the 
ability of the Fos/Jun complex to bind an AP-1 consensus 
site (Farrell et al., 1989). An AP-1 consensus sequence 
(MS-AP-1) is located in the promoter of an EB early gene, 
BSLF2-BMLF1 (MS-EA) (Farrell et al., 1989). ZEBRA can 
transactivate transcription through this site, although it 
is not yet clear whether AP-1 sequences are required for 
transactivation of EB viral genes in infected lymphocytes 
(Holley-Guthrie et al., 1990, Urier et al., 1989).
ZEBRA also binds sites on the EBV genome which deviate 
from the AP-1 consensus sequence (Flemington and Speck, 
1990b, Lieberman and Berk, 1990, Lieberman et al., 1990, 
Packham et al., 1990, Urier et al., 1989). The 
autoregulated BZLF1 (ZEBRA) promoter contains three 
divergent AP-1 elements (Flemington and Speck, 1990b). Two 
sites, TGAGCCA (ZIIIA) and TTAGCAA (ZIIIB), 105-129 bp 
upstream of the transcriptional start site are arranged in a 
tail to tail fashion and are separated by 6 nucleotides. An 
additional AP-1 sequence, TGACATCA (Z-AP-1 octamer), is 
located further downstream at -67. This sequence, which was 
first identified in the iun promoter by Angel et al., 
mediates activation by TPA and Jun/AP-1 (Angel et al.,
1988). Recent work has shown that although this site is TPA 
inducible in the ZEBRA promoter, it does not appear to be 
transactivated by ZEBRA (Flemington and Speck, 1990a,
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1990b).
Since both ZEBRA and Fos/Jun are involved in 
transcriptional regulation of gene expression it was 
important to compare the DNA binding activities of these 
proteins. Therefore, we studied the relative DNA binding 
affinities of ZEBRA and a Fos-GCN4 chimera for the divergent 
AP-1 sites found in the autoregulated BZLF1 promoter.
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RESULTS
Binding of ZEBRA and Fos-GCN4 to Oligonucleotides Bearing 
Single AP-1 and "AP-1 Like" Sequences. It was previously 
shown that ZEBRA footprinted sites ZIIIA at -129 (TGAGCCA) 
and ZIIIB at -116 (TTAGCAA), but not the Z-AP-1 octamer 
sequence (TGACATCA) 67 bp upstream of the BZLF1 
transcriptional start site (Flemington and Speck, 1990b,
Fig. 1A). A gel retardation assay was used to compare the 
relative affinities of ZEBRA and Fos-GCN4 for these sites in 
the BZLF1 promoter. The Fos basic domain has been shown to 
bind the AP-1 consensus site as a homodimer when fused to 
the GCN4 leucine zipper (Hope and Struhl, 1987, Kouzarides 
and Ziff, 1989, Sellers and Struhl, 1989). A Fos-GCN4 
chimera, expressed as a trpE fusion protein, bound the MS- 
AP-1 consensus site but not ZIIIB or ZIIIA. ZIIIB differs 
from the consensus AP-1 site at 3bp and ZIIIA contains a 
single base pair change from the consensus heptanucleotide 
AP-1 sequence (Fig. 3B). Fos-GCN4 bound the Z-AP-1 octamer 
with high affinity whereas ZEBRA interacted only weakly with 
this sequence. Thus, Fos-GCN4 binds the AP-1 octamer and 
heptanucleotide sequences while ZEBRA binds the MS-AP-1, 
ZIIIA and ZIIIB sites with relatively high affinity (Fig.
IB). The trpE-ZEBRA and trpE-Fos-GCN4 fusion proteins were 
derived from the urea solubilized fraction of total E. coli 
protein extracts. ZEBRA and Fos-GCN4, expressed in this 
system, bind DNA as homodimers (refer to chapter III, Kolman
92
Reproduced with permission o f the copyright owner. Further reproduction prohibited w ithout permission.
et al., manuscript in preparation, Taylor et al., 1991b). A 
control extract of bacterial protein did not exhibit 
specific binding to any of these sites (data not shown). 
Binding of ZEBRA and Fos-GCN4 to an Oligonucleotide 
Containing Two ZEBRA Response Elements, ZIIIA and ZIIIB. 
Since the ZIIIA and ZIIIB sites are only separated by 6 
nucleotides in the ZEBRA promoter, we studied the ability of 
ZEBRA and Fos-GCN4 to bind both sites simultaneously. An 
oligonucleotide termed "Double" which includes both sites in 
the orientation found in the BZLF1 promoter was used in gel 
band shift assays. ZEBRA was able to bind two sites on this 
oligonucleotide simultaneously as demonstrated by the 
appearance of two band shift products in a mobility shift 
assay (Fig. IB). Suprisingly, the Fos-GCN4 chimera, which 
did not bind a single ZIIIA or ZIIIB site, was able to bind 
the Double oligonucleotide (ZIIIA + ZIIIB) generating a 
slower migrating complex (Fig. IB).
The order of binding to sites on the Double 
oligonucleotide was then studied. Serial dilutions of ZEBRA 
and Fos-GCN4 were incubated with 4 X 10'13M of 32P labelled 
Double probe. At low protein concentrations (0.25 ul),
ZEBRA only bound a single site on the oligonucleotide (one 
shifted complex) while at high concentrations (5 ul) it 
began to interact with both sequences on a single 
oligonucleotide molecule (two shifted complexes) (Fig. 2A). 
However, Fos-GCN4 generated a single complex of slower
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mobility with the Double probe, regardless of protein 
concentration (Fig. 2B).
Nucleotide Specificity of ZEBRA and Fos-GCN4 Binding Sites.
Point mutations were introduced into the MS-AP-1, ZIIIA, and 
ZIIIB oligonucleotides in an attempt to establish which base 
pairs mediate specific DNA binding by ZEBRA and Fos-GCN4.
The oligonucleotides created were MS-AP-1* (TTAGTCA), ZIIIA* 
(TGAGCAA) and ZIIIB* (TGAGCAA). ZIIIA* and ZIIIB* contain 
an identical 7 bp core recognition site (TGAGCAA), but 
differ in their surrounding sequences (see Experimental 
procedures). Additionally, the ZIIIA and ZIIIB 
oligonucleotides were mutated at 4 positions to generate the 
ZIIIAm and ZIIIBm oligonucleotides.
ZEBRA bound with relatively high affinity to the MS-AP- 
1, ZIIIA and ZIIIB sequences containing a single point 
mutation (MS-AP-1*, ZIIIA*, ZIIIB*) (Fig. 3A). However, it 
was unable to bind either the ZIIIAm or ZIIIBm sites which 
contain 4 base pair changes (Fig. 3A). The lack of binding 
to the ZIIIAm or ZIIIBm sites confirms the importance of the 
identified core element. Fos-GCN4 was more fastidious in 
its binding site requirements; it recognized the ZIIIB* 
(TGAGCAA) sequence, but did not interact with any of the 
other mutated oligonucleotides (Fig. 3B). ZIIIA* and ZIIIB* 
differ from the AP-1 consensus at 2 nucleotides, while ZIIIB 
differs at 3 positions and ZIIIA differs at only one.
ZIIIA* and ZIIIB* contain the same 7 bp recognition sequence
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but their surrounding sequences vary. These results suggest 
that ZEBRA is considerably more tolerant of changes within 
the 7 bp recognition sequence than Fos-GCN4.
Competition Analysis to Determine the Affinities of ZEBRA 
and Fos—GCN4 for AP-1 and ZEBRA Promoter Sequences. The 
relative affinities of ZEBRA and Fos-GCN4 for AP-1 related 
sequences were assayed by competition analysis (Fig. 4). 
Complex formation between ZEBRA or Fos-GCN4 and the MS-AP-1 
probe were assayed in the presence of three concentrations 
of cold competitor oligonucleotides. The relative reduction 
of AP-1 complex formation is proportional to the affinity of 
ZEBRA or Fos-GCN4 for the oligonucleotide competitor. 
Disruption was quantified by comparing the integrated 
intensity of each shifted complex as a function of the 
concentration of oligonucleotide competitor (Figs. 4C and 
D) . The ZEBRA complex formed with the MS-AP-1 site was most 
efficiently competed with MS-AP-1, ZIIIA*, and ZIIIB* (Figs. 
4A and 4C). A 5 fold molar excess of these oligonucleotides 
eliminated ZEBRA binding to 32P labelled MS-AP-1, whereas a 
50 fold molar excess of ZIIIA, ZIIIB, or Double 
oligonucleotide was required to achieve a similar level of 
inhibition (Figs. 4A and C). The ZEBRA/MS-AP-1 complex was 
minimally reduced by the addition of a 50 fold molar excess 
of Z-AP-1 octamer and was not affected by the addition of 
unlabeled ZIIIAm, ZIIIBm, or a control oligonucleotide with 
no AP-1 like sequences (Figs. 4A, 4C and data not shown).
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Thus, ZEBRA, binds with highest affinity to TGAGTCA (MS-AP-1) 
and TGAGCAA (ZIIIA* and ZIIIB*) sites and with a lower 
affinity to TTAGCAA (ZIIIB), TGAGCCA (ZIIIA), TTAGTCA (MS- 
AP-1*) , and the Double oligonucleotide (Figs. 4C and 5).
The Fos-GCN4/MS-AP-1 complex was efficiently competed 
with a 5 fold molar excess of Z-AP-1 octamer, 20 fold excess 
of MS-AP-1 or a 50 fold molar excess of ZIIIB* (Figs. 4B and 
4D). Suprisingly, the Double oligonucleotide which was 
bound by Fos-GCN4 in a gel retardation assay was unable to 
disrupt the formation of a complex at the MS-AP-1 site 
(Figs. 2, 4B and 4D). None of the remaining divergent AP-1 
sites competed with the formation of a Fos-GCN4/MS-AP-l at a 
50 fold molar excess (data not shown). A second competition 
experiment was also quantified; the relative affinities of 
ZEBRA and Fos for the various oligonucleotides was found to 
be the same in both experiments (data not shown).
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DISCUSSION
Binding Site Specificities of ZEBRA and Fos-GCN4. ZEBRA and 
Fos bind similar DNA sequences, and both ZEBRA expression 
and TPA treatment result in activation of EBV lytic viral 
DNA replication (Chevallier-Greco et al., 1986, Countryman 
and Miller, 1985, Gradoville et al., 1990, Taylor et al., 
1989, zur Hausen et al., 1978). An underlying biological 
question is whether Fos, or other cellular AP-1 proteins, 
mediate TPA induction of the EBV lytic cycle. While this 
question has not been addressed directly, I have begun by 
assessing the binding affinities of ZEBRA and Fos-GCN4 for 
several sites in the BZLF1 and MS-EA promoters. I chose to 
compare ZEBRA binding to that of Fos-GCN4 since the first 
indication that ZEBRA was a DNA binding transactivator came 
from a recognition of the homology between the basic domains 
of ZEBRA and c-fos (Farrell et al., 1989). Although Fos 
generally binds in-vivo as a Fos/Jun heterodimer, an 
artificial Fos-GCN4 construct, containing the Fos basic 
domain fused to the GCN4 leucine zipper, was used in order 
to allow Fos to bind DNA as a homodimer. Many groups have 
previously shown that that the target site specificity of a 
protein is not affected by the nature of its leucine zipper 
(Kouzarides and Ziff, 1989, Nakabeppu and Nathans, 1989, 
Neuberg et al., 1989a and Sellers and Struhl, 1989).
ZEBRA bound a much broader range of DNA sequences 
than did Fos-GCN4 (Fig. 2). ZEBRA bound the palindromic AP-
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1 site, but also bound the ZIIIA and ZIIIB sites which do 
not contain perfect dyads. Unexpectedly, oligonucleotides 
with base pair substitutions which disrupt the partial dyad 
nature of ZIIIA or ZIIIB (TGAGCCA to TGAGCAA or TTAGCAA to 
TGAGCAA) were bound by ZEBRA with increased affinity (Fig.
3, Fig. 5). This departs from the proposed "scissors-grip" 
model of DNA binding by dimeric proteins, in which each 
protein monomer is hypothesized to bind an identical DNA 
"half-site" (Vinson et al., 1989). Although it is known 
that ZEBRA (expressed in vitro or as a trpE fusion protein) 
binds DNA as a homodimer (Chang et al., 1990, Flemington and 
Speck, 1990c, Kolman et al., 1991, Lieberman and Berk, 1990, 
Taylor et al., 1991b), it is unclear whether both monomers 
contact or recognize symmetrical units on DNA. There are 
two possibilities which could explain ZEBRA binding to 
assymetric sites: first, only one subunit of the ZEBRA 
homodimer contacts DNA; or second, each subunit recognizes a 
wide variety of half-site sequences, thereby recognizing 
asymmetric sequences. Our preliminary data suggests that 
the second hypothesis accounts for ZEBRA'S asymmetrical 
recognition of DNA (Kolman et al., 1991, Taylor et al.,
1991b). It has also been found that the homodimeric 
glucocorticoid receptor binds DNA asymmetrically and is more 
sensitive to mutations in the right half of its binding site 
(reviewed in Beato, 1989).
Fos-GCN4 binds as a homodimer to the palindromic AP-1
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site (Hope and Struhl, 1987, Kouzarides and Siff, 1989, 
Sellers and Struhl, 1989, Fig. 1). Both Fos/Jun 
heterodimers and artificial Fos homodimers have been shown 
to recognize the AP-1 consensus sequence asymmetrically 
(Risse et al., 1989). This suggests that the Fos basic 
domains in a homodimer interact with heptamer target 
sequences in a manner equivalent to a Fos/Jun heterodimer. A 
Fos-GCN4 homodimer did not bind any of the divergent AP-1 
sites with high affinity. It was unable to recognize ZIIIA, 
ZIIIB, or ZIIIA*, all of which were recognized by ZEBRA 
homodimers (Figs. 2 and 5). Fos-GCN4 bound ZIIIB* (TGAGCAA) 
but not ZIIIA* even though both oligonucleotides contain the 
same heptamer core sequence. This result suggests that 
flanking nucleotides influence binding ability. ZIIIB*, but 
not ZIIIA*, contains the bases CA and TG adjacent to the 
recognition sequence increasing the dyad symmetry of the 
site, CATGAGCAATG. The importance of flanking sequences in 
the binding affinity of Fos was noted by Nakabeppu and 
Nathans (1989). They found that substitutions of cytosine 
(C) and guanosine (G) for adenine (A) and thymine (T) bases 
at flanking positions 1 and 10 of the cyclic AMP response 
element resulted in greater than a 90% decrease of 
homodimeric Fos or Fos/Jun binding activity (Nakabeppu and 
Nathans, 1989). This novel result indicates that the 
binding site specificity of Fos is broader than originally 
proposed; Fos-GCN4 can bind an asymmetric heptamer sequence
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with two mismatches from the AP-1 consensus in an 
appropriate flanking oligonucleotide environment.
While ZEBRA has a broader specificity than Fos-GCN4 in 
recognizing various heptamer sequences related to the AP-1 
consensus, only Fos-GCN4 binds the Z-AP-1 octamer sequence 
(TGACATCA) located in the BZLF1 promoter with high affinity. 
This is interesting since this site was originally defined 
as the Jun/AP-1 response element in the iun promoter and is 
TPA responsive (Angel et al., 1988b). Thus, ZEBRA is unable 
to bind a subset of the known AP-l/TPA responsive elements.
Fos/Jun as well as artificial Fos homodimers are known 
to bind the octamer cAMP response element (CRE) (TGACGTCA) 
which differs from Z-AP-1 octamer at the 5th position (G to 
A) (Chang et al., 1990, Flemington and Speck, 199a,
Nakabeppu and Nathans, 1989, Nakabeppu et al., 1988, Risse 
et al., 1989, Sellers and Struhl, 1989). While the sites 
are similar, Deutsch et al. have shown that they have 
different signal-responsive properties, that is, CREs are 
not responsive to TPA (Deutsch et al., 1988). Chang et al. 
have shown that ZEBRA does not bind a CRE element (Chang et 
al., 1990). Although ZEBRA does not bind the TPA responsive 
Z-AP-1 octamer site, binding to this site may be important 
in the induction of the EBV lytic cascade. For example, Fos 
or another cellular AP-1 protein may bind this site in vivo 
(Angel et al., 1988b, Angel et al., 1987, Deutsch et al., 
1988, Lee et al., 1987) leading to low levels of transcrip-
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tion from the BZLF1 promoter. ZEBRA, could then bind to the 
ZIIIA and ZIIIB sites in the BZLF1 promoter resulting in 
autoactivaton of this gene (Flemington and Speck, 1990b). 
Binding of ZEBRA and Fos-GCN4 to an Oligonucleotide with Two 
Binding Sites. We studied ZEBRA and Fos-GCN4 binding to the 
Double oligonucleotide in which the ZIIIA and ZIIIB 
heptamers occur as they are arranged in the BZLF1 promoter: 
oriented head to tail and separated by six base pairs. Two 
ZEBRA response elements, ZRE1 (TGTGTAA) and ZRE2 (TGAGCAA) 
(identical to the heptamer core sequence in the ZIIIA* and 
ZIIIB*), are arranged in a similar manner, separated by 10 
bp in ori lyt (Lieberman et al., 1990). This arrangement 
may be a common mode of targetting ZEBRA transcriptional 
control in the EBV genome.
These results show that two ZEBRA homodimers can bind 
ZIIIA and ZIIIB simultaneously on the Double oligonucleotide 
(Fig. 1). We have not determined which site is filled 
initially although footprinting data has demonstrated that 
ZEBRA binds ZIIIB with higher affinity than ZIIIA 
(Flemington et al., 1990b, Lieberman and Berk, 1990). Gel 
shift experiments with limiting dilutions of ZEBRA protein 
show that both sites are bound only after a significant 
portion of single sites are filled. Furthermore, 
competition experiments indicate that ZEBRA does not have a 
greater affinity for the Double oligonucleotide than for 
either single site (Figs. 4A and 4C). Thus, ZEBRA binds
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non-cooperatively to these sites. However, binding of ZEBRA 
to these two adjacent sites may allow for synergistic 
transactivation.
Fos—GCN4, which did not bind oligonucleotides bearing 
single ZIIIA or ZIIIB sites, bound the Double 
oligonucleotide (containing ZIIIA and ZIIIB) as a high 
molecular weight complex (Figs. 1 & 2). The association of 
this slow mobility complex can be disrupted by addition of 
ZEBRA protein suggesting that the two proteins compete for a 
similar sequence on the Double probe (unpublished data). 
However, the Double oligonucleotide did not interfere with 
Fos-GCN4/MS-AP-l complex formation (Figs. 4B and D). One 
explanation for this phenomenon is that these associations 
are non-competitive because the two probes bind different 
Fos-GCN4 complexes. The MS-AP-1 probe is bound by a Fos- 
GCN4 homodimer whereas the Double probe may only bind a Fos- 
GCN4 complex with more than two monomers and perhaps with 
other proteins. Alternatively, Fos-GCN4 might bind the 
Double oligonucleotide indirectly through a second protein 
which is not required for binding to the MS-AP-1 site.
Several groups have recently examined ZEBRA binding 
activity in EBV promoters and the origin of EBV lytic 
replication (ori lyt) (Farrell et al., 1989, Flemington and 
Speck, 1990b, Hardwick et al., 1988, Kenney et al., 1988, 
Lieberman and Beerk, 1990, Lieberman et al., 1990, Packham 
et al., 1990, Urier et al., 1989) but there had been no
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studies directly comparing the ability of Fos and ZEBRA to 
bind the same sites. Since our work was completed Chang et 
al. (1990) reported on the binding specificities of ZEBRA 
and Fos/Jun in ori lyt. Our work on the binding 
specificities of ZEBRA and Fos for sites in the BZLF1 and 
MS-EA promoters provides both complementary and novel 
observations. Chang et al. demonstrated that ZEBRA binds an 
AP-1 consensus site with higher affinity than divergent 
heptamer sites in ori lyt, whereas we have found that it 
binds equivalently to an AP-1 site as well as a divergent 
sequence (ZIIIA* or ZIIIB*) (Chang et al., 1990). ZIIIA* 
and ZIIIB* contain the same core heptamer sequence found in 
ZRE2 in ori lyt (Chang et al., 190). The two studies show 
that Fos/Jun and Fos-GCN4 are restrictive in binding 
divergent AP-1 heptamer sites. However, we have found novel 
binding of a Fos-GCN4 homodimer to a divergent heptamer 
sequence flanked by dyad symmetry (ZIIIB*).
The interaction of ZEBRA with cellular AP-1 sequences 
may result in the displacement of Fos or other cellular AP-1 
factors, thereby precluding their activity. Alternatively, 
by binding AP-1 sites, ZEBRA may transactivate (or possibly 
transrepress) cellular genes in a manner analogous with 
cellular AP-1 transcription factors. AP-1 proteins are 
probably not able to activate transcription of EBV genes 
through ZEBRA responsive elements because at least one AP-1 
binding protein, Fos-GCN4, is unable to bind those sites.
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The divergent nature of the ZEBRA responsive sites makes it 
unlikely that cellular AP-1 proteins can have an ongoing 
role promoting viral transcription and activating the EBV 
lytic cycle. Additionally, the ability of Fos to bind the 
TPA responsive Z-AP-1 octamer and CRE sites, which are not 
bound by ZEBRA, indicates that ZEBRA can not simply 
substitute for Fos. The ability of these related proteins 
to bind similar as well as distinct sites adds yet another 
level of complexity to the relationship of these 
transactivators in regulating cellular and viral gene 
expression.
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Figure 1. Binding specificity of ZEBRA and Fos-GCN4 for AP- 
1 and BZLF1 promoter sequences (Zp) . (A) Sequences of the
ZEBRA (BZLF1) and MS (BSLF2-BMLF1) promoters. AP-1 like 
sequences are underlined (Farrell et al., 1989, Flemington 
and Speck,1990b) and the transcriptional start site of the 
BZLF1 gene is marked. (B) Gel retardation assay showing the 
specificities of trpE (vector) , trpE-ZEBRA (Z1_2A5) and trpE- 
Fos-GCN4 (F0S-GCN4) proteins for oligonucleotides containing 
the AP-1 and Zp sequences; Z-AP-1 octamer, ZIIIA, and ZIIIB 
(Flemington and Speck, 1990b). The Double oligonucleotide 
contains sites ZIIIA and ZIIIB in the orientation found in 
the BZLF1 promoter. Equivalent amounts of bacterially 
expressed fusion proteins were incubated with each 
oligonucleotide (4 X 10'13M) for thirty minutes prior to 
analysis of the retardation complexes by gel 
electrophoresis.
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Figure 2. Binding of ZEBRA and Fos-GCN4 to the Double 
oligonucleotide. ZEBRA and Fos-GCN4 proteins were titrated 
in a gel retardation assay with 4 X 10 "13M 32P-labeled MS- 
AP-1 or Double (ZIIIA + ZIIIB) probe. Various volumes of 
protein extract (shown as ul in the figure) were incubated 
with the MS-AP-1 or Double probe in the presence of poly 
dldC. ZEBRA and Fos-GCN4 both bind to the MS-AP-1 site as a 
single complex indicated as S. Mobility shift complexes 
with a slower mobility are indicated as D.
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Figure 3. Gel retardation assay illustrating the binding 
specificities of ZEBRA and Fos-GCN4 for mutant recognition 
sequences. MS-AP-1, ZIIIA, and ZIIIB oligonucleotides were 
mutated at a single position (noted by a *); the base 
substitution is underlined. Two oligonucleotides mutated at 
multiple positions are designated ZIIIAm and ZIIIBm. The 
control oligonucleotide contains no AP-1 related sequences. 
Bacterially expressed trpE-ZEBRA (A) or trpE-Fos-GCN4 (B) 
was incubated with these 32P-labeled oligonucleotides and 
binding was analyzed by a mobility shift assay.
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Figure 4. Competition experiment to evaluate the affinity 
of ZEBRA, and Fos-GCN4 for AP-1 and ZEBRA promoter sites. 4 
X 10'13M 32P- labeled MS-AP-1 oligonucleotide was incubated 
with bacterially expressed trpE-ZEBRA (A) or trpE-Fos-GCN4 
(B) in the presence of three concentrations of cold 
competitor DNA. Complex formation was resolved by gel 
electrophoresis. Only the shifted complexes are shown and 
the nature of the competitor and its molar excess over the 
MS-AP-1 probe is indicated. (C) These results were 
quantified by scanning the relative intensity of each 
shifted complex. The percent disruption of the ZEBRA/MS-AP- 
1 complex is plotted for each oligonucleotide competitor.
The stippled portion of each bar represents the percent 
disruption with a 5 fold molar excess of oligonucleotide 
competitor, while the shaded area represents the additional 
disruption with a 20 fold molar excess of competitor. (D) 
Results were quantified as in (C) for disruption of the Fos- 
GCN4/MS-AP-1 complex.
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Figure 5. Evaluation of ZEBRA and Fos-GCN4 binding site 
affinities. Affinities were determined from the competition 
analysis in Fig. 4. Nucleotide substitutions in the 
recognition sequences are noted by bold type. The relative 
affinities are marked with 1 representing the highest 
affinity while a dash (-) indicates that the protein did not 
bind the sequence specifically.
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Affinities of ZEBRA and Fos/GCN4 for 




Name Promoter Oligonucleotide n
MS-AP-1 BSLF2 TCTTCATGAGTCAGTGCTTC 1 2
MS-AP-1 * -- TCTTCA^TAGTCApTGCTTC 2 —
Z-AP-1
(Octamer)
BZLF1 CTAGAAACCAt G ACAT CAj3AG AGG AT C 3 1
ZIIIA BZLF1 CTAGCTATGCAfTGAGCCApAGATC 2 —
ZIIIA* — CTAGCTAT GCATG AGCA/\CAGAT C 1 —
ZIIIB BZLF1 CTAGCAGGCAfTTGCTAAtTGTACCGATC 2 —
ZIIIB* — CTAGCAGGCATTGCTCArGTACCGATC t 3






THE UNIQUE DNA BINDING ACTIVITY OP ZEBRA IS INHIBITED 
BY CASEIN KINASE II PHOSHPORYLATION
INTRODUCTION
I have recently studied the DNA binding activity of the 
Epstein-Barr viral replication activator, ZEBRA (Taylor et 
al., 1991a). This protein has sequence homology to the 
Fos/Jun family in its basic domain (exon II) and shares the 
ability of these proteins to bind an AP-1 consensus site 
(Farrell et al., 1989). However, ZEBRA is also able to bind 
divergent AP-1 sites not bound by Fos or Jun (Chang et al., 
1990, Flemington and Speck, 1990b, Lieberman et al., 1990, 
Packham et al., 1990, Taylor et al., 1991, Urier et al.,
1989) .
Both ZEBRA and Fos contain potential casein kinase II 
(CKII) phosphorylation sites directly upstream of their 
basic DNA binding domains (Fig. 1). Casein kinase II is a 
ubiquitous protein kinase present in both the cytoplasm and 
nucleus of eukaryotic cells (Hathaway and Traugh, 1982, 
Edelman et al., 1987). Studies using synthetic peptides 
have shown that CKII preferentially phosphorylates serine or 
threonine residues situated 5' to clusters of acidic amino 
acids (Marin et al., 1986, Kuenzel et al., 1987). CKII also 
appears to selectively phosphorylate residues adjacent to
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predicted B-turns (Hathaway and Tragh, 1982).
CKII activity is stimulated by mitogens such as serum, 
TPA, insulin, insulin-like growth factor and epidermal 
growth factor (Ackerman and Osheroff, 1989, Carroll and 
Marshak, 1989, Carroll et al., 1988, Karlund and Czech,
1988, Sommercorn et al., 1987). This suggests that CKII may 
play a role in the regulation of cell growth. Additionally, 
it has been determined that a large number of nuclear 
oncoproteins satisfy the substrate requirements for casein 
kinase II (CKII) phosporylation (Carroll et al., 1988, Krebs 
et al., 1988). The SV40 large T antigen, P53 tumor 
suppressor protein, HPV E7 oncoprotein, c-Myc, c-Myb and 
serum response factor (SRF) have all been shown to be 
specifically phosphorylated by CKII (Barbosa et al., 1990, 
Carroll et al., 1988, Grasser et al., 1988, Krebs et al., 
1988, Luscher et al., 1990, 1989, Manak et al., 1990, Meek 
et al., 1990).
While the physiological role of kinases has not been 
definitively determined for any system, they have been 
implicated in the regulation of various protein functions. 
CKII has recently been shown to uniquely affect DNA binding 
of two unrelated proteins. CKII phosphorylation inhibits 
DNA binding by the c-myb oncogene but enhances the binding 
activity of the serum response factor, a factor which 
mediates Fos transcription (Luscher et al., 1990, Manak et 
al., 1990). Phosphorylation of a protein with an acidic
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activator domain, such as that present in GAL4 or GCN4, has 
been hypothesized to enhance transcriptional activity by 
increasing net negative charge (Carroll et al., 1988, Hope 
and Struhl, 1988, Ma and Ptashne, 1987, and Ptashne, 1988). 
Both GAL4 and GCN4 contain potential CKII sites within the 
acidic domain (Carroll et al., 1988). Although this 
hypothesis has not been proven, protein phosphorylation has 
been shown to upregulate transcriptional activation of CREB 
and the yeast heat shock factor as well as DNA replication 
by SV40 (Sorger and Pelham, 1988, Virshup et al., 1989, 
Yamamoto et al., 1988, Dwarki et al., 1990, reviewed,
Edelman et al., 1987).
Thus, it was of interest to determine whether the 
potential CKII acceptor sites found within the acidic 
domains of ZEBRA and the related Fos protein are 
phosphorylated. I have determined that only ZEBRA is 
phosphorylated by CKII in-vitro. Additionally, I have found 
that CKII specific phosphorylation of ZEBRA results in a 
reversible inhibition of DNA binding.
118
Reproduced with permission o f the copyright owner. Further reproduction prohibited w ithout permission.
RESULTS
CKII Differentially Affects ZEBRA and Fos Phosphorylation. A
TrpE-ZEBRA fusion protein as well as purified ZEBRA protein 
(expressed in E.coli) were used to study the ability of CKII 
to specifically phosphorylate the ZEBRA protein (Carey et 
al., 1991, Taylor et al., 1991a). These proteins were 
incubated with purified CKII and [Y-32p]ATP and analyzed by 
autoradiography following SDS-polyacrylamide gel 
electrophoresis (Carroll et al., 1988, Carroll and Marshak, 
1988). Labelled phosphate was transferred to a casein 
substrate as well as to the TrpE-ZEBRA and purified ZEBRA 
proteins (Fig. 2). However, a control E. coli extract with 
trpE protein was not phosphorylated by CKII (Fig. 2).
Additionally, labeled phosphate was not incorporated in the
\/ZEBRA protein when [.<- P]ATP was added without CKII (data 
not shown).
Since ZEBRA has been hypothesized to be related to the 
Fos oncogene protein and the two proteins have related DNA 
binding specificities, we were interested in determining 
whether the two proteins may be similarly modified by kinase 
activity. Both proteins contain potential CKII sites in 
similar positions, directly 5# to the basic DNA binding 
domain (Fig. 1) (Carroll et al., 1988, Farrell et al., 1989, 
Taylor et al., 1991a). CKII phosphorylation of a trpE-Fos- 
GCN4 fusion protein was studied. This fusion protein 
contains the basic DNA binding domain of Fos (aa 126-162,
119
Reproduced with permission o f the copyright owner. Further reproduction prohibited w ithout permission.
which includes the potential CKII phosphorylation site) 
fused in frame to the GCN4 leucine zipper. It has 
previously been shown that the GCN4 leucine zipper does not 
affect the binding specificity of the Fos protein but allows 
it to bind DNA as a homodimer (Abate et al., 1990,
Kouzarides and Ziff, 1989, Nakabeppu and Nathans, 1989, 
Sellers and Struhl, 1989). Unlike ZEBRA, this protein was 
not phosphorylated by CKII (Fig. 3). Additionally, a TrpE- 
Fos fusion protein containing only Fos amino acids 12 6-162 
was not phosphorylated (data not shown).
Happing the CKII Specific Phosphorylation Sites in ZEBRA. A
panel of ZEBRA deletion mutants were utilized to map the 
CKII specific phosphorylation sites (Taylor et al., 1991a). 
These proteins, which were all expressed as TrpE fusion 
proteins in E. coli. were incubated with purified CKII plus 
[\̂ -32P]ATP and analyzed by autoradiography following 
polyacrylamide electrophoresis (Fig. 3, Taylor et al.,
1991). The smallest ZEBRA deletion proteins which could be 
phosphorylated by CKII were Z141_245, Z4111_159, Z^.^, and Z168_202 
localizing the CKII phosphorylation region to amino acids 
.160-198 (Fig. 3 and data not shown) . The two serines which 
are potentially phosphorylated in this region are S-167 and 
S—173 (refer to Fig. 1). Although the ZEBRA deletion 
protein, Z172_245 , was not phosphorylated in this assay, Z168_202 
was a substrate, suggesting that S-173 is an acceptor site 
for CKII phosphorylation but requires a few of the upstream
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acidic residues for its phosphorylation. S-167, if it were 
an acceptor site, would not be expected to be phosphorylated 
in the ZEBRA deletion mutant WZ,.^. CKII phosphorylation 
requires the presence of acidic residues downstream of the 
acceptor site (i.e. aa 168-176) not present in this 
construct (Fig. 3) (Marin et al., 1986, Kuenzel et al.,
1987) .
CKII Phosphorylation Inhibits ZEBRA Specific DNA Binding.
ZEBRA has previously been shown to bind a consensus AP-1 
sequence as well as divergent heptamer sites (Chang et al., 
1990, Farrell et al., 1989, Flemington and Speck, 1990b, 
Liberman et al., 1990, Packham et al., 1990, Taylor et al., 
1991a, Urier et al., 1989). We analyzed the effects of CKII 
phosphorylation on ZEBRA'S ability to bind AP-1 as well as 
divergent sites. Purified ZEBRA protein was preincubated 
with CKII and ATP and then exposed to the 32P-labeled AP-1 
oligonucleotide probe. DNA binding was assayed by 
determining the level of retarded complex in a mobility 
shift gel. Untreated ZEBRA protein bound the AP-1 
oligonucleotide with high affinity as did ZEBRA extracts 
preincubated with only CKII or ATP (Fig. 4). However, 
binding to the AP-1 oligonucleotide was almost completely 
inhibited when ZEBRA protein was preincubated with both ATP 
and CKII (Fig. 4). CKII phosphorylation also inhibited 
ZEBRA binding to divergent AP-1 sites located in the ZEBRA 
promoter (ZIIIA, ZIIIB, and AP-l-octamer) (data not shown,
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refer to Experimental Procedures or Taylor et al., 1991, for 
sequences of oligonucleotides).
It has previously been shown that protein phosphatase 
2A (PP2A) can reverse CKII phosphorylation (Luscher et al., 
1990, reviewed Cohen and Cohen, 1989). Therefore, following 
a 15 minute preincubation of ZEBRA with ATP and CKII, 
extracts were treated with PP2A for an additional 15 
minutes. When ZEBRA from these extracts was analyzed for DNA 
binding activity, a partial recovery of DNA binding activity 
was obtained (Fig.4). This result suggests that 
phosphorylation of the ZEBRA protein does not irreversibly 
inhibit its DNA binding activity.
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DISCUSSION
CKII Phosphorylation of ZEBRA. We have demonstrated that 
ZEBRA serves as a substrate for CKII phosphorylation in- 
vitro. ZEBRA contains two potential CKII acceptor sites at 
serine-167 and serine-173. ZEBRA deletion mutants have been 
used to show that these serines are contained within the 
region phosphorylated by CKII (aal60-198). The data 
presented here suggest that serine-173, and possibly S-167, 
are phosphorylated by CKII (Fig. 3). Further biochemical 
characterization including sequence analysis of two 
dimensional phosphopeptide maps will be conducted to confirm 
this result.
Although there is no data concerning the 
phosphorylation state of ZEBRA in-vivo. ZEBRA was 
specifically phosphorylated by CKII in-vitro. Another 
serine-threonine protein kinase, the cAMP dependent protein 
kinase (Slice and Taylor, 1989), was unable to phosphorylate 
the ZEBRA protein in-vitro (Taylor, unpublished data).
Interestingly, the expression and activity of CKII in- 
vivo is influenced by factors which also affect ZEBRA 
expression. ZEBRA, which triggers activation of the EBV 
lytic cycle, is activated by phorbol esters (zurHausen et 
al., 1978, Biggin et al., 1987, Laux et al., 1988).
Similarly, CKII activity is elevated in homogenates of cells 
treated with various mitogens including the phorbol ester, 
TPA (Carroll et al., 1988). Alternatively, ZEBRA may be
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phosphorylated in-vivo by the EB viral gene product, BGLF4, 
which has sequence homology with other serine/threonine 
kinases (Kolman, J.L. , personal communication, Smith and 
Smith, 1989).
CKII Phosphorylation of Fos. Fos, which has a potential 
CKII acceptor site (Carroll et al., 1988) in a region 
similar to ZEBRA, was not phosphorylated by CKII in-vitro 
(Fig. 3, Curran and Marshak, personal communication).
Several potential CKII sites in c-myc were also not 
phospiiorylated by CKII in-vitro (Luscher et al., 1989).
Thus, CKII phosphorylation may not be determined solely by a 
protein's primary structure.
However, the c-Fos serine-133, which corresponds to S- 
167 in ZEBRA, is also conserved in Jun (S-249) and GCN4 
leucine zipper proteins. Since this work was completed, it 
has been determined that c-Jun is phosphorylated in-vitro at 
S-249 as well as T-239 and S-243 by glycogen synthase kinase 
3 (Boyle et al., 1991). Protein kinase C dephosphorylation 
of c-Jun at one or more of these sites resulted in increased 
DNA binding (Boyle et al., 1991). Therefore, 
phosphorylation, albeit by different kinases, may similarly 
affect ZEBRA and some of the related basic-leucine zipper 
proteins.
Effects of CKII Phosphorylation on ZEBRA DNA Binding. The
effects of CKII phosphorylation on DNA binding have 
previously been studied for c-myb and the serum response
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factor, SRF (Luscher et al., 1990, Manak et al., 1990). In- 
vitro DNA binding activity of SRF was enhanced by CKII 
phosphorylation, while binding of c-myb was inhibited by 
phosphorylation (Luscher et al., 1990, Manak et al., 1990). 
We have found that ZEBRA, like c-myb, is negatively 
regulated by CKII phosphorylation. CKII phosphorylation 
abrogated ZEBRA'S ability to bind all of its target DNA 
sequences (Fig. 4 and data not shown).
While ZEBRA's ability to bind DNA is crucial for its 
role in transactivating early EB viral genes, the potential 
function of the ZEBRA protein in the late phase of lytic 
replication has not yet been studied (Flemington and Speck, 
1990b, Kenney et al., 1989, Packham et al, 1990, Rooney et 
al., 1989, Urier et al., 1989). Our data suggests that 
ZEBRA is a very stable protein with a half life of greater 
than 48 hours (Taylor and Hagmeier, unpublished results, 
refer to chapter II). Additionally, it has recently been 
shown that ZEBRA associates with a late EB viral protein 
(Katz et al., manuscript in preparation). Therefore, 
regulation of ZEBRA's ability to bind DNA may be required 
during the late phase of EB viral replication if the protein 
serves additional functions in the lytic cascade.
Effects of CKII Phosphorylation on ZEBRA Transactivation.
CKII phosphorylation has been hypothesized to increase the 
level of transactivation by acidic activators by increasing 
their net negative charge (Carroll et al., 1988, reviewed
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Ptashne, 1988). Phosphorylation by protein kinase A and 
other serine/threonine kinases has been shown to increase 
the transcriptional activity of CREB and yeast heat shock 
factor (Yamamoto et al., 1988, Sorger and Pelham, 1988).
However, it is difficult to explain how CKII 
phosphorylation could increase transcriptional activation in 
the case of ZEBRA or c-myb. Since phosphorylation of these 
two proteins inhibits their DNA binding activity, one would 
have to invoke a model in which ZEBRA or c~myb 
transactivates transcription as a DNA binding protein and/or 
as a soluble factor. It is of interest to note that v-myb 
has been reported to transactivate certain promoters (e.g., 
human hsp70) in the absence of its DNA binding domain 
(Klempnauer et al., 1989). Alternatively, phosphorylated 
ZEBRA may interact with a second DNA binding factor, thereby 
activating transcription at novel sequence elements. The 
extent of phosphorylation of the herpes simmplex virus gene 
product, ICP4, has been shown to modulate its ability to 
form complexes on specific DNA sequences (Papavassiliou et 
al., 1991).
The activation domains of the ZEBRA and myb proteins 
have not been definitively determined. It is possible that 
they do not contain acidic activators and that CKII 
phosphorylation affects DNA binding but not transactivation. 
This hypothesis is presently being studied by using ZEBRA 
proteins mutated at serine-167 in transactivation assays
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(Kolman,J.L. personal communication).
Effects of CKII Phosphorylation on ZEBRA Nuclear 
Localization. Recent evidence suggests that CKII 
phosphorylation may also affect the relocalization of 
proteins between the cytoplasm and nucleus (Rihs et al., 
1991). Rihs and coworkers have shown that the rate of 
nuclear transport of SV40 large T antigen was affected by 
mutagenesis of two serines which are phosphorylated by CKII 
in-vitro (Grasser et al., 1988, Rih et al., 1991). Although 
the SV40 T antigen nuclear localization signal (NLS) was 
necessary and sufficient for nuclear localization, wild type 
large T-antigen accumulated in the nucleus after 30 minutes 
while the mutant protein required 12 hours to achieve the 
same degree of partition (Rih et al., 1991).
The CKII acceptor site in SV40 large T antigen is 
located 13 aa 5' to the basic NLS (Rih et al., 1991). 
Potential CKII sites are located approximately 15 amino 
acids upstream of many proteins harboring nuclear 
localization sequences, including polyoma T, adenovirus Ela, 
c-myc, p53 and c-rel (Rih et al., 1991). Most of these 
proteins have not yet been tested for CKII phosphorylation. 
However, ZEBRA fits the CKII site/NLS motif well. The 
ZEBRA NLS has recently been localized to a region within the 
basic domain of the protein (Giot et al., 1991), located 
immediately downstream of the CKII phosphorylation site. The 
effects of CKII on the rate of nuclear transport of ZEBRA
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may be another mechanism by which phosphorylation regulates 
ZEBRA'S role in the EB lytic cycle.
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Figure 1. Schematic representation of ZEBRA and Fos. (A) 
Several structural domains in both proteins are indicated 
potential casein kinase II phosphorylation sites in both 
ZEBRA and Fos (denoted CKII); the basic domains of both 
proteins; the coiled-coil domain in ZEBRA and the leucine 
zipper motif in Fos. (B) Amino acid sequences of the 
potential CKII phosphorylation sites and basic domain of 
ZEBRA and Fos (Biggin et al., 1987, van Straaten et al., 
1983). The serines which are possible acceptor sites for 
CKII phosphorylation are indicated in bold type (S). 
Conserved residues in the ZEBRA and Fos basic domains are 
marked by lines (Farrell et al., 1989).
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Figure 2. Phosphorylation of ZEBRA by casein kinase II.
ZEBRA protein purified from E. coli (Carey et al., 1991) or 
expressed as a TrpE fusion protein was incubated with CKII 
in the presence of [}j-32P]ATP at 37C for 15 minutes.
Proteins were then electrophoresed on an 8% SDS- 
polyacrylamide gel and analyzed by autoradiography. 
Phosphorylation of casein was used as a positive control and 
trpE protein was used as a negative control.
131













Reproduced with permission o f the copyright owner. Further reproduction prohibited w ithout permission.
Figure 3. Mapping the casein kinase II phosphorylation site 
in ZEBRA and Fos. (A) Various ZEBRA deletion mutants were 
used to map the sites phosphorylated by CKII in ZEBRA.
Total protein from bacteria which carried various TrpE-ZEBRA 
deletion proteins was resolved by SDS-polyacrylamide gel 
electrophoresis and stained with Coomassie brilliant blue.
(B) Protein extracts from each of the ZEBRA deletion mutants 
as well as a Fos-GCN4 construct was incubated with CKII in 
the presence of [^-^PjATP at 37C for 15 minutes. Proteins 
were then electrophoresed on an 8% SDS-polyacrylamide gel 
and analyzed by autoradiography. These mutants localize the 
CKII phosphorylation site(s) in ZEBRA can to amino acids 
160-198. A Fos-GCN4 construct containing the potential Fos 
CKII site was not phosphorylated in vitro.
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Figure 4. Phosphorylation of ZEBRA by CKII inhibits DNA 
binding. Purified ZEBRA protein was preincubated with CKII, 
ATP, or CKII + ATP for 15 minutes at 37C. Protein 
phosphatase 2A (PP2A) was added for 15 minutes following 
pretreatment with CKII + ATP. All extracts were then 
incubated with a 32P-labeled oligonucleotide containing the 
AP-1 consensus sequence for 20 minutes at room temperature 
(22C). Complexes were electrophoresed on a 4% acrylamide 
gel in 0.5X TBE.
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CHAPTER VI
CONCLUSIONS
Activation of the Latent EBV Genome. The discovery that 
ZEBRA induces lytic EB viral DNA replication suggested that 
it may function as a transactivator of lytic genes 
(Countryman et al., 1985, 1987, Gradoville et al., 1990, 
Rooney et al., 1988, Takada et al., 1986). Several groups 
have shown that promoters in the EB origin of lytic 
replication (orilyt) and several early genes: BZLF1, BRLF1 
(R), BMLF1 (MS-EA) and BMRF1 (EA-D) are responsive to ZEBRA 
activation (Chavrier et al., 1989, Chevallier-Greco et al., 
1986, Flemington et al., 1990b, Gradoville et al., 1990, 
Kenney et al., 1989a, Lieberman et al., 1989, Sinclair et 
al., 1991, Takada et al., 1986, Urier et al., 1989).
However, ZEBRA expression is not sufficient to induce 
release of infectious EB virions in Raji cells or a tightly 
latenty X50-7.17 subclone (Gradoville et al., 1990, reviewed 
in Miller, 1990b). This suggests that although ZEBRA can 
directly activate a group of EBV early genes, additional 
factors are required for late gene expression and virion 
production.
A second EBV transactivator encoded by the BRLF1 open 
reading frame (termed R) has been identified (reviewed in 
Hayward and Hardwick, 1991). This protein is also expressed 
early in the lytic cycle, but is incapable of inducing viral
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replication in the absence of ZEBRA (Cox et al., 1990). The 
R transactivator is encoded as a bicistronic mRNA; the 
complete BRLF1 open reading frame is encoded together with 
the downstream BZLF1 sequences (Biggin et al., 1987, Manet 
et al., 1989). R transactivates expression from the EBV 
origin of lytic replication (orilyt), the BMLF1 early gene 
promoter, the HIV-1 long terminal repeat (LTR) and 
positively regulates its own expression (BRLF1 promoter) 
(Chevalier-Greco et al., 1989, Cox et al., 1990, 
Hammerschmidt and Sugden, 1988, Hardwick et al., 1988,
Kenney et al., 1989b, Quinlivan et al., 1990, Sinclair et 
al., 1991). Recent evidence suggests that R and Z may act 
synergistically to activate transcription of a subset of EBV 
early genes (Cox et al., 1990, Giot et al., 1991, Kenney et 
al., 1989b). Furthermore, R has been shown to be one of the 
factors necessary for ZEBRA activation in EBV negative cells 
(Kenney et al., 1989b).
Transcription of ZEBRA. The work presented in chapter II 
indicates that ZEBRA expression is differentially regulated 
in standard and defective EB viruses. Novel upstream and 
downstream sequences present in het DNA are responsible for 
activation of ZEBRA expression (Fig 1-2, Rooney et al.,
1988). Two BZLF1 specific mRNAs, 3.5 Kb and 0.9 Kb, are 
spontaneously expressed in cells harboring a het virus but 
are only synthesized by the standard latent virus after 
chemical induction (Fig 11-10, Taylor et al., 1989).
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Initiation of the two transcripts has been mapped to the 
BRLF1 and BZLF1 promoters, respectively (Manet et al., 1989, 
Biggin et al., 1987). The 3.5 Kb mRNA represents the 
bicistronic message encoding both the R and ZEBRA 
transactivators (Fig. 11-11, Biggin et al., 1987, Manet et 
al., 1989).
It is interesting to note that no novel BZLF1 mRNAs 
were detected in cells (clone 5) harboring the het virus 
(Fig. 11-10, 11-15). The 0.9 Kb BZLF1 specific mRNA can be 
transcribed by either the het or standard EB genome, whereas 
the 3.5 Kb message can only be transcribed by the standard 
virus. The rearrangements in HR-1 clone 5 het DNA result in 
a deletion of most of the BRLF1 open reading frame (refer to 
Fig. I-II). The kinetics of transcription and decay of both 
mRNAs were identical in clone 5 cells (Fig. 11-15, Taylor 
and Hagmeyer, unpublished data). Thus, even when ZEBRA 
expression is aberrantly regulated in the defective genome, 
transcription of BRLF1 and BZLF1 are closely linked. 
Coordinate expression of these two mRNAs may be mediated by 
different mechanisms since Sinclair et al. (1991) recently 
showed that the BZLF1 promoter is responsive to TPA while 
the BRLF1 promoter is not. Alternatively, stimulation of 
transcription at both the BZLF1 and BRLF1 promoters may be 
mediated by low levels of the ZEBRA transactivator 
(Flemington and Speck, 1991b). WZhet may spontaneously 
produce enough het ZEBRA to activate the standard promoters
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in clone 5 cells. TPA, on the other hand, activates 
endogenous AP-1 transcription factors (Angel et al., 1987, 
Lee et al., 1987) which may induce transcription of the 
standard BZLF1 promoter. ZEBRA produced in this way could 
then auto-stimulate the BZLF1 promoter (0.9 Kb transcript) 
and initiate transcription from the BRLF1 promoter (3.5 Kb 
transcript).
In contrast to the results of Giot et al. (1991), I did 
not observe a decreased level of transcription of the BRLF1 
and BZLF1 bicistronic mRNA when ZEBRA was expressed 
spontaneously from the het genome (Fig. 11-10). The 
importance of the R transactivator in regulating induction 
of the EBV lytic cycle awaits the development of a system 
for recovering mutant viral genomes.
ZEBRA DNA Binding. DNA binding is often required for 
transcriptional activation by transactivators. The 
demonstration that ZEBRA shares homology with members of the 
cFos family (Farrell et al., 1989) suggested that it may 
bind a consensus AP-1 site and activate promoters which 
carry a copy of this sequence. Indeed, ZEBRA has been shown 
to transactivate the c-fos promoter in a chloramphenicol 
acetyl transferase (CAT) assay although it was unable to 
activate the c-jun promoter (Flemington and Speck, 1990d). 
Furthermore, AP-1 transactivators may regulate ZEBRA 
expression via an AP-1 octamer sequence located in the BZLF1 
promoter (refer to chapter III, Flemington and Speck, 1990b,
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Taylor et al., 199a). This finding suggests that ZEBRA, and 
some AP-1 proteins may function together to regulate 
induction of the lytic cycle.
ZEBRA directly binds an array of related DNA motifs 
including a consensus heptamer AP-1 sequence (refer to 
chapter III, Chang et al., 1990, Farrell et al., 1989, 
Flemington and Speck, 1990b, Packham et al., 1990, Lieberman 
and Berk, 1990, Lieberman et al., 1990, Taylor et al.,
1991a, Urier et al., 1989). The various EBV genes which were 
found to be transactivated by ZEBRA, including BZLF1, BRLF1, 
orilyt, BMRF1 and BMLF1, all contain ZEBRA binding sites in 
their promoters (Chang et al., 1990, Farrell et al., 1989, 
Flemington and Speck, 1990b, Kenney et al., 1989b, Packham 
et al., 1990, Lieberman and Berk, 1990, Lieberman et al.,
1990, Sinclair et al., 1991, Taylor et al., 1991a, Urier et 
al., 1989). Although many of the ZEBRA binding sites do not 
contain a dyad symmetry, ZEBRA binds DNA as a dimer and 
requires two intact basic domains for DNA binding activity 
(refer to chapter III, Chang et al., 1990, Kolman et al.,
1991, Taylor et al., 1991a, 1991b).
Regulating ZEBRA DNA binding activity. Regulation of ZEBRA 
DNA binding activity may be important in the EBV lytic 
cycle. It has recently been shown that DNA binding activity 
can be regulated by phosphorylation, redox potential and 
dimerization (refer to chapter V, Abate et al., 1990b, Boyle 
et al., 1991, Luscher et al., 1990, Manak et al., 1990, Sun
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and Baltimore, 1991). Additionally, phosphorylation of an 
inhibitory protein, termed IP-1, inhibits DNA binding of 
Fos-Jun heterodimers (Auwerx and Sassone-Corsi, 1991) .
ZEBRA, but not the related Fos protein, can be 
phosphorylated in-vitro by casein kinase II (CKII). ZEBRA 
phosphorylation results in an abrogation of its DNA binding 
activity to all target sequences (refer to chapter V).
Abate and co-workers have found that DNA binding of 
Fos-Jun heterodimers is modulated by a reduction-oxidation 
of a single conserved cysteine in the basic DNA-binding 
domains of the two proteins (Abate et al., 199ob). This 
cysteine is conserved in the basic domain of ZEBRA, and as 
is the case for Fos-Jun heterodimers, ZEBRA is unable to 
bind DNA in the absence of a reducing agent (DTT) (Taylor, 
N., unpublished data). Thus, regulation of the redox or 
phosphorylation state of ZEBRA (or a related regulatory 
protein) may influence ZEBRA DNA binding activity in-vivo.
Regulation of the dimerization potential of leucine 
zipper and helix-loop-helix (HLH) proteins is important for 
DNA binding activity and specificity. As discussed in 
chapter IV, DNA binding of basic-leucine zipper (bzip) 
proteins is regulated by dimerization potential. A GCN4 
leucine zipper homodimerizes whereas a fos zipper dimerizes 
specifically with jun and jun dimerizes with itself or fos 
(Kouzarides and Ziff, 1989, Neuberg et al., 1989, Sellers 
and Struhl, 1989, Nakabeppu and Nathans, 1989). The binding
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specificities of these proteins is also modulated by 
dimerization (Benbrook and Jones, 1990, Gounari et al.,
1990, Kara et al., 1990, Ivashkiv et al., 1990). 
Additionally, the E12 bHLH protein can form homo-or 
heterodimers, but only binds DNA as a heterodimer and the 
myc bHLH-zip protein only binds DNA as a heterodimer 
(Blackwood and Eisenman, 1991, Sun and Baltimore, 1991).
ZEBRA, which dimerizes via a coiled-coil interaction 
(Flemington and Speck, 1990c), homodimerizes and fails to 
interact with the leucine zipper domains of GCN4 or jun 
(refer to chapter III, Chang et al., 1990, Kolman et al.,
1991, Taylor et al., 1991b). Target proteins which 
heterodimerize with ZEBRA, thereby regulating DNA binding 
activity and transactivation, may be identified by screening 
cDNA expression libraries. One candidate for 
heterodimerization is the human heat shock protein, hsp70, 
which shares homology with ZEBRA at amino acid positions 
important for the formation of a coiled-coil (Kolman, J.L., 
personal communication). Additionally, ZEBRA associates 
with a late EB viral protein which may modify its activity 
(Katz et al., manuscript in preparation).
Regulation of ZEBRA activity. ZEBRA transactivation is 
regulated by EBV and cellular factors: ZEBRA activation of 
orilyt, BRLF1, BMRF1 and BMLF1 is enhanced by an interaction 
with R; ZEBRA acts synergistically with the HIV-1 tat 
transactivator to activate the HIV-1 LTR; and ZEBRA acts
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synergistically with c-myb to activate the BMRF1 and SV40 
early promoters (Chevallier-Greco et al., 1989, Holley- 
Guthrie et al., 1990, Kenney et al., 1989a, manuscript 
submitted, Lieberman et al., 1988, Mallon et al., 1990, 
Sinclair et al., 1991). Although the importance of these 
various factors in regulating ZEBRA activity in-vivo has not 
yet been determined, these results suggest that interactions 
with cellular and viral transcription factors are required 
for disruption of EBV latency.
The properties of monomer proteins determines the 
transactivation activities of Fos/Jun heterodimers (Chiu et 
al., 1989, Nakabeppu and Nathans, 1991, Schutte et al.,
1989). Heterodimers of c-Fos or c-Jun with Jun-B or a 
naturally truncated form of FosB, respectively, are 
transactivation deficient (Schutte et al., 1989, Nakabeppu 
and Nathans, 1991). A truncated BZLF1 cDNA containing BRLF1 
sequences fused to 3' exon I sequences of BZLF1 has been 
identified (Manet et al., 1989). While the function of this 
protein has not been determined, it may heterodimerize with 
ZEBRA and thus, alter its target recognition sequence or 
transactivation potential.
Several groups have recently attempted to map the ZEBRA 
activation domain (Baumann et al., manuscript in 
preparation, Carey et al., manuscript in preparation, Giot 
et al., 1991, Rooney et al., 1990). It is generally agreed 
that the activation domain is encoded by exon I of ZEBRA but
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there is some disagreement as to the precise amino acids 
responsible for activation. Additionally, Baumann and 
colleagues have found that the ZEBRA transactivation domain 
may be distinct from a second domain required for disruption 
of EBV latency (Baumann et al., manuscript in preparation). 
Thus, the process by which ZEBRA and associated proteins 
induce the EBV lytic cycle promises to be complex.
The role of EBV replication in disease. Activation of EBV 
has been observed in oral hairy leukoplakia, an AIDs 
associated lesion (Greenspan et al., 1985). Defective viral 
DNA containing a rearrangement of BamHI W to BamHI Z 
sequences, similar to the recombination found in P3HR-1, has 
been identified in 2 of 10 oral hairy leukoplakia lesions 
(Patton et al., 1990). Furthermore, antibodies to ZEBRA as 
well as spontaneous lytic EB viral DNA replication are found 
in AIDS patients, but not in control individuals. These 
data suggest that activation of ZEBRA (by recombination or 
other processes) is important in the pathogenesis of OHL 
(Alsip et al., 1988, Patton et al., 1990, Joab et al.,
1991). The mechanisms by which ZEBRA expression is 
suppressed and activated in-vivo may remain an enigma for a 
few more years.
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EXPERIMENTAL PROCEDURES
Cell Lines
HH514-16 (clone 16) is a prototypic HR-1 subclone which 
contains standard Epstein-Barr virus but lacks het virus. 
Clone HH543-5 (clone 5) harbors hypermolar levels of het DNA 
in addition to standard EB virus (Rabson et al., 1982). The 
B95-8 cell line is a marmoset cell line derived by 
cocultivation of marmoset cells with a human lymphoblastoid 
cell line (Miller et al., 1982). These cell lines were 
grown in RPMI 1640 with 8% fetal calf serum, penicillin, 
amphotericin B (Fungizone) and streptomycin.
COS-1 cells were grown in Dulbecco modified Eagle 
medium with 8% fetal bovine serum.
Chemical Induction and Inhibition
HR-1 cells were induced with sodium butyrate (3 mM) or 
TPA (20 ng/ml). In some experiments, induction was 
accompanied by inhibition of viral DNA replication with 100 
ug of phosphonoacetic acid (PAA) per ml (Summers and Klein, 
1976).
Transcription and translation were inhibited with 5 ug/ml 
actinomycin or 10 ug/ml cyclohexamide, respectively. 
Transfections
COS-1 cells were transfected by the DEAE-dextran 
method, followed by chloroquine treatment (Luthman and 
Magnusson, 1983). COS-1 cells were seeded at a 1:5 split
146
Reproduced with permission o f the copyright owner. Further reproduction prohibited w ithout permission.
ratio in 100-mm dishes 72 hours prior to transfection. The 
medium was removed and the cells were incubated with 10 ug 
of plasmid DNA and 300 ug DEAE-dextran suspended in TS 
(0.14M NaCl, 0.005M KC1, 0.7M Na2HP04, 0.025M Tris HC1, 
0.002M MgCl2, 0.002M CaCl2, pH 7.4) for 60 minutes at 37C in 
5% C02. The cells were washed once with TS and were then 
resuspended in DMEM with 5% FCS containing 100 um 
chloroquine (Sigma). Following a 4 hour incubation, the 
medium was replaced with DMEM plus 5% FCS and incubation 
continued for 72 hours.
Cells used for immunoflourescence were seeded in 60-mm 
dishes containing coverslips. Transfections were carried 
out as described above.
Plasmids
PSV2neo plasmids containing either WZhet (the het BamHI 
fragment from defective EBV containing the BZLF1 open 
reeading frame) or the standard BamHI Z fragment from EBV 
FF41 or HR-1 have been described by Countryman et al.
(1987) . A 679 bp Nael-PvuII fragment encompassing the 
unspliced BZLF1 open reading frame, WZ.,_167, (including exon I 
and 41 amino acids from the first intron) was isolated from 
WZhet. The overhanging end produced by PvuII digestion was 
filled in with the Klenow fragment of DNA polymerase and 
deoxynucleotide triphosphates. The fragment was inserted 
into the unique Smal site of the trpE bacterial expression 
bector pATH 11, which was the gift of T.J. Koerner via M.
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Carlson (Taylor et al., 1989, Dieckmann and Tzagaloff,
1985) . Deletion mutants of WZV167(+41) were constructed as 
follows: WZ^gg was cloned by excision of the Hindlll 
fragment of WZ.,_167(+41); WZ133-167(+41) was cloned as a Smal- 
Hindlll fragment into pATH 10; and WZ133_167(+4) was cloned as a 
SmaI-Sau3A fragment into pATH 10.
The full length BZLF1 cDNA (aal-aa245) (Manet et al., 
1989) was cloned as a Nael-BamHI fragment into the Sxnal- 
BamHI sites of pATH 11. The BZLF1 cDNA was the gift of A. 
Sergeant. BZLF1 deletion mutants were constructed as 
follows: Zl41_245 was cloned as a Nhel-BamHI fragment, Z172_245 
was cloned by deletion of sequences upstream of an internal 
BsmI site in Z,,_245, Z,.^ was cloned as a Nael-PstI fragment, 
and Z1m227 was cloned from a B95-8 ZEBRA cDNA (Farrell et al., 
1989) as a BamHI-HincII fragment. All fragments were cloned 
into the appropriate sites of pATH vectors. Z2jno-i59 was 
constructed by R. Baumann following BAL31 digestion of Z,.^ 
at the unique Nhel site (aa 141). The 2nd exon of BZLF1, 
z167-202' was doned from genomic BamHI Z as a PvuII-HincII 
fragment.
Mutant ZEBRA proteins were constructed by E. Flemington 
using site directed mutagenesis. The BZLF1 open reading 
frame cloned in SP64 was the gift of P. Farrell (Farrell et 
al., 1989). A Hindlll -EcoRI fragment containing aa88-245 
was cloned into the XhoI-EcoRI sites of pBluescript KS 
(Stratagene). Amino acids 178-180 and 187-189 were then
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mutated from KRY to EEL and RKC to EES, respectively, in two 
additional constructs. Site directed mutagenesis was 
performed as described by the manufacturer (BioRad).
A trpE Fos-GCN4 chimera was constructed by John Kolman. 
The fos basic domain (aa 126-162) was fused to the GCN4 
leucine zipper (aa 251-281) at an introduced Xhol site.
This construct was the kind gift of T. Kouzarides and E.
Ziff (Kouzarides & Ziff, 1989). This clone was inserted
into the BamHI and Xbal sites of the pATH 1 trpE expression
vector and is termed Fos-GCN4 or FG, fos basic domain (F) 
fused to a GCN4 leucine zipper (G). The inserts were 
sequenced by John Kolman using the Sanger dideoxynucleotide 
protocol modified for use with double stranded DNA clones. 
Expression of TrpE-Fusion Proteins
TrpE fusion proteins were expressed as described 
previously (Kleid et al., 1981). Escherichia coli AG1 
containing the various TrpE-fusion proteins were grown 
overnight in LB. The cells were then diluted 1:10 in M9 
medium containing 1% Casamino Acids (Difco Laboratories, 
Detroit, Mich.) and 100 ug/ml of ampicillin. Cells were 
induced for four hours with 20 ug/ml of indoleacrylic acid 
after having reached an optical density of 0.2 at 600 nm. 
Bacteria were pelleted and stored at -20C.
Fusion protein was enriched by preparation of an 
insoluble protein fraction (Kleid et al., 1981, Klempnauer 
and Sippel, 1987). One hundred ml of bacteria were pelled
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and resuspended in 10 ml TEN (lOmM Tris, pH 7.8; lmM EDTA; 
50mM NaCl) with 1 mg/ml lysozyme. 220 ul Nonidet P-40 
(NP40) was added after 15 min and incubation continued for 
10 min on ice. 15 ml of a Nacl-Mg solution (1.5M NaCl; 12 
mM MgCl2) containing 100 ul of 2 mg/ml DNAse was added and 
the sample was nutated at 4C for one hour. Insoluble 
material was washed twice with TEN.
Fusion protein was either resuspended in SDS-sample 
buffer for gel electrophoresis or dissolved in 6m urea for 
DNA binding reactions. Proteins used for DNA binding 
reactions were first visualized by SDS-polyacrylamide gel 
electrophoresis and stained with Coomassie brilliant blue in 
order to approximate the level of induced fusion protein in 
each preparation. The volume of cells containing equivalent 
amount of fusion protein (3.5 to 5 mis) were pelleted and 
resuspended in 1 ml of 6m urea (Angel et al., 1988a). Cells 
were sonicated twice for 20 s each. The urea solubilized 
protein fraction was dialyzed three times for 45 min at 4C 
against 15mM Hepes, pH 7.9; 75mM KC1; 0.2mM EDTA; lmM DTT 
and 7.5% glycerol. In some heterodimer experiments, 
equivalent amounts of two fusion proteins were solubilized 
together in urea prior to dialysis.
Tmmnni nations
TrpE-WZ.,_167(+41) (ZEBRA exon I) fusion protein expressed 
from 50 ml of cells was recovered in the insoluble protein 
fraction and electrophoresed on an 8% preparative SDS-
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polyacrylamide gel. The gel was stained with Coomassie 
brilliant blue and strips containing the fusion protein were 
ground and emulsified in complete Freund adjuvant (0.5 ml 
per rabbit). Rabbits were immunized by subcutaneous 
injection and boosted every 2 weeks with an equivalent 
amount of protein (approximately 25 mg) emulsified in 
incomplete Freund adjuvant (0.5 ml per rabbit). Serum was 
collected 1-2 weeks following each boost (Taylor et al.,
1989).
Tmmunofiuorescence
Following transfections on coverslips for 72 hours, 
coverslips were air-dried, fixed in a 2:1 acetone:methanol 
solution and stored at -20C prior to use. The coverslips 
were incubated for 1 hour at 37C with a 1:50 dilution of 
ZEBRA specific antibody in PBS++ (PBS plus lmM CaCl2 and 
0.5mM MgCl2) . Coverslips were washed with PBS++ for 10 
minutes and then incubated with a 1:50 dilutin of a 
rhodamine-conjugated anti-rabbit immunoglobulin for an 
additional 1 hour at 37C. Final washes were in PBS++ for 2 
minutes (X5) followed by an H20 rinse. Coverslips were 
inverted and mounted in buffered glycerol (90% glycerol 
buffered with 0.4M Na-bicarbonate, pH9.5) on standard 
microscope slides.
Protein Electrophoresis and Western Blotting
Proteins were electrophoresed by the method of Laemmli 
(Laemmli, 1970). Protein samples were suspended in sample
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buffer (200 mM Tris, pH 6.8; 15% 2-mercaptoethanol; 1% SDS; 
30% glycerol; 0.002% bromophenol blue). Mammalian cell 
extracts were sonicated for 20s and all samples were heated 
at 100C for 5 minutes. Samples were electrophoresed in a 
discontinuous buffer system using vertical slab 
electrophoresis at 200 volts. The stacking gels were 4% 
acrylamide (30:0.8 polyacrylamide:bis-acrylamide) in 0.125M 
Tris pH 6.8 and the resolving gels were typically 8% 
polyacrylamide in 0.375M Tris pH 8.8.
Proteins were either detected directly by staining or 
were transferred to nitrocellulose for immunoblotting. 
Proteins were directly stained with Coomassie brilliant blue 
(0.1% Coomassie brilliant blue in 30% methanol and 10% 
glacial acetic acid) and destained with 30% methanol, 10% 
acetic acid.
Alternatively, proteins were electrotransferred to 
nitrocellulose filters in 0.25M Tris, 0.15M glycine, 0.1% 
SDS, and 25% methanol using a Bio-Rad transblot apparatus 
for 2 hours at 200 mAmps at 4C (Towbin et al., 1971,
Burnette et al., 1981). Nitrocellulose filters were blocked 
in Blotto (5% non-fat dry milk, 10‘4% anti-foam A (Sigma) ,
0.5 uM thimerisol) at room temperature for 1-12 hours with 
gentle agitation (Johnson et al., 1984). The filters were 
nutated for 1 hour in Blotto with 1:100 to 1:1000 dilutions 
of a ZEBRA-specific rabbit antibody or a polyvalent human 
serum, RM, which detects latent EBV proteins as well as a
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p21 late viral protein (Rowe et al., 1987). Filters were 
washed twice for 20 minutes in TS (10 mM Tris, pH 7.4; 0.9% 
NaCl; 0.05% Tween-20) and incubated with a 1:2,000 dilution 
of 125I-labelled staphylococcal protein A (0.5-1.0 uCi) 
(Amersham) in Blotto for 60-90 minutes. Filters were then 
further washed in TS, dried and exposed to Kodak XAR-5 or 
BB-5 films with intensifying screens.
Protein Phosphorylations
Purified ZEBRA protein as well as fusion proteins were 
phosphorylated in casein kinase buffer (75mM KC1; 5 mM 
MgCl2; 10 mM Hepes, pH 7.9; 1 mM EGTA and 0.5mM DTT).
Fusion proteins (100 ng, 2 ul) were made as described above 
while ZEBRA protein (250 ng) was purified by ammonium 
sulfate precipitation following overexpression in E. coli 
using the tac expression vector pRW76. The protein was 90% 
pure as judged by coomasie blue staining of SDS- 
polyacrylamide gels (Carey et al., manuscript submitted). 
Proteins were phosphorylated in the presence of lOuCi of [^- 
32P] ATP and 5 ul of CKII. Following incubation at 37C for 
15 minutes samples were denatured by boiling and 
electrophoresed on an 8% SDS-polyacrylamide gel as described 
above.
Radiolabeled DNA
Purified DNA fragment probes for northern blot analysis were 
electroeluted from TBE-polyacrylamide gels and radiolabelled 
by the random primer method (Feinberg and Vogelstein, 1983).
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DNA fragments which were used as probes are as follows: the 
5' BamHI-Hindlll fragment of WZhet mutant 80 which contains 
2 64 bp upstream of BZLF1 and 259 bp of the first BZLF1 
coding exon; a 395 bp fragment from the Hindlll site in 
BZLF1 encoding the 31 region of exon I; a 627 bp BamHI-PstI 
fragment from the BZLF1 cDNA which encodes exons I and II; 
and a 538 bp SacI-BamHI fragment which is specific for the 
BRLF1 open reading frame. Typically, 100 ng of double 
stranded DNA was denatured by incubation at 100C for 5 
minutes in the presence of random hexamers (Pharmacia) and 
then cooled on ice for 5 minutes. The DNA was then labelled 
with 33 uCi of 32P-dCTP (Amersham) and 5 units of the Klenow 
fragment of E. coli DNA polymerase in Klenow buffer (50 mM 
Tris-HCl, pH 7.2; 10 mM MgS04, 0.1 mM DTT, 50 ug /ml bovine 
serum albumin) containing 3 uM unlabelled dATP, dGTP, and 
dTTP. Reactions were incubated at room temperature for 
several hours. DNA probes for south-western analysis were 
prepared by nick translation (Rigby et al., 1977). DNA (100 
ng) was incubated for 90 minutes at 15C in Klenow buffer 
with 1.25 ng of DNAse (Worthington) and 10 units of E. coli 
DNA polymerase 1 (New England Biolabs) containing 3 uM 
unlabelled dATP, dGTP, and dTTP and 33 uCi of 32P-dCTP. 
Oligonucleotides were end-labelled in Klenow buffer in the 
presence of 5 units of Klenow and 32P-labelled 
deoxynucleotides for 30 minutes at room temperature. DNA 
fragment probes were purified from unincorporated label
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using G-50 sephadex columns while oligonucleotide probes 
were purified over G-4 columns.
Northern Blots
Total cellular RNA or cytoplasmic RNA was harvested 
from uninduced cells and at various times following 
induction. Total RNA was isolated by the guanidium 
isothiocyanate method essentially as described by Chirgwin 
et al. (1979). Approximately 5 X 107 cells were resuspended 
in ice cold GIT (4M guanidine isothiocyanate; 0.025M NaOAC, 
pH 6.0; 1.5M B-mercaptoethanol) and layered on top of 4 ml 
cesium chloride buffer (5.7M CsCl; 0.0125M NaOAC, pH 6.0) in 
an SW41 polyallomer tube. Tubes were filled completely with 
GIT and centrifuged in an SW41 rotor at 32,000 RPM for 21 
hours at 2 0C. The RNA pellet was precipitated in ethanol 
and stored at -70C prior to use.
Cytoplasmic RNA was isolated by lysis of cells in an 
NP40 buffer. 5 X 107 cells were resuspended in 187 ul of 
150 mM NaCl and 10 mM Tris, pH 8.0 containing 5 units of 
RNAsin on ice. Lysis was achieved by the addition of 14 ul 
of 10% NP-40 and cytoplasmic RNA was isolated in the 
supernatant following centrifugation in a microfuge for 1 
minute at 4C. The supernatant was removed into an equal 
volume of a urea solution (7M urea; 350mM NaCl; 10 mM Tris, 
pH 7.5; 20 mM EDTA; 1% SDS) and extracted twice with phenol: 
chloroform (1:1) prior to precipitation with ethanol.
RNA was electrophoresed on 1% agarose gels containing
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IX MOPS (20xnM MOPS; 5xnM NaOAC; lmM EDTA) and 6% formaldehyde 
at 200V in a running buffer which contained IX MOPS and 6% 
formaldehyde. RNA was resuspended in IX MOPS, 6% 
formaldehyde and 50% formamide and heated at 70C for 10 
minutes prior to the addition of gel loading buffer (xylene 
cyanol and bromophenol blue in 25% glycerol). Gels were 
transferred to nytran overnight in 2OX SSC following washes 
in ddH20; 50mM NaOH and 10 mM NaCl; 0.1M Tris, pH 7.5; and 
ddH20.
rRNA bands were visualized by soaking the filter in 5% 
acetic acid and then staining with 0.004% methylene blue in 
0.5M NaOAC, pH 5.2 (Davis et al., 1986).
Blots were hybridized according to the method of Church 
and Gilbert (1984). Blots were prehybridized for 3 hours - 
overnight at 65C in a sodium phosphate mix (0.5M NaPf, pH 
6.8; 7% SDS; 1% BSA; 0.1 mM EDTA) and denatured probe was 
then added directly to the mix for an additional 16-24 hours 
at 65C. Radiolabelling of probes is described in a separate 
section. Blots were washed 3X for 15 minutes at 65C in 40 
mM NaPj, 0.5% BSA, 5% SDS, and lmM EDTA. Two final washes 
were carried out in 40 mM NaP,-, 1% SDS and lmM EDTA.
Filters were exposed to Kodak XAR-5 or BB-5 film with 
intensifying screens.
Gel Retardation Assays
DNA binding reactions using gel shift mobility assays 
were first described by Fried and Crothers (1981). The gel
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retardation assays performed in this study were modified 
from the procedures of Farrell et al. (1989). Reactions 
containing 4 X 10’13M of the appropriate 32P end-labelled 
double stranded oligonucleotide and 2 ul of individual trpE 
fusion proteins (approximately 100 ng) or 4 ul of a mixture 
of two proteins were incubated in 25 microliters of binding 
solution (15 mM Hepes, pH 7.9; 75mM KC1; 0.2mM EDTA; lmM 
DTT; 7.5% glycerol; 1 ug poly dldC) for 30 minutes at room 
temperature or 4C. Competition assays were conducted with 
5, 2 0 and 50 fold molar excesses of unlabelled competitor 
over the 32P labelled MS-AP-1 oligonucleotide. (The Double 
oligonucleotide was used in 2.5, 10 and 25 fold molar 
excesses since it contains two potential binding sites 
(ZIIIA and ZIIIB)). The reactions were electrophoresed 
under non-dissociating and non-denaturing conditions in 4% 
polyacrylamide-0.5X TBE (44 mM Tris-borate, 1 mM borate, 1 
mM EDTA) at room temperature or 4C. Gels were then dried on 
a Bio-Rad slab gel drying apparatus and autoradiographed.
Gel retardation assays involving casein kinase II were 
performed in a 30 ul volume of casein kinase buffer 
(described above). 250 ng of purified ZEBRA protein was
incubated at 37C for 15 minutes in the presence of 5 ul of 
casein kinase II (purified from bovine testes,Carroll et 
al., 1988, 1989) and 1 ul of 10 mM ATP (Pharmacia). Some 
extracts were then subject to treatment with 1 ul protein 
phosphatase 2A (PP2A) (10‘5 units) for an additional 15
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minutes at 37C. PP2A was stored in 50 mM Tris, pH 7.5 and
0.1% BSA and was the kind gift of Jonathan Chernoff. 32P 
labelled oligonucleotide probe and 1 ug of poly dldC were 
added to each sample and the reactions were incubated for an 
additional 30 minutes at 22C. Samples were then 
electrophoresed as described above.
Films from competition experiments were quantified by 
densitometer scanning on a Kodak Bioimage densitometer with 
Visage 2 000 software. Disruption of complex formation was 
determined by comparing the ratio of shifted complex in 
lanes with and without competitor.
Synthetic Oligonucleotides
The synthetic double stranded oligonucleotides used in 
binding studies were as follows (sequence reflects top 
strand in a 5' to 3' direction): Core sequences are










(contains ZIIIA + ZIIIB)
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Z-AP-1 octamer: CTAGAAACCATGACATCACAGAGGATC
Control oligo: TGGCATGCTGCTGACATCTGGC
All oligonucleotides had overhanging Xbal sites at the 5' 
end and overhanging BamHI sites at the 3' end, with the 
exception of the AP-1 and Double oligonucleotides which had 
CT and AG overhangs at the 5' and 3' ends, respectively. 
Nitrocellulose DNA-bindinq Assays
Immunoblotting was performed as described above. Incubation 
with radiolabeled DNA (south-westerns) followed the 
procedure described by Bowen et al. (1980) and Klempnauer 
and Sipper (1987). Following blocking of immunoblots for 1 
hour in Blotto, the blots were washed three times (20 
minutes each) with 6M urea; 0.2% NP-40 and four times (30 
minutes each) with DNA-binding buffer (10 mM Tris-HCl, pH 
7.8; 1 mM EDTA; 50 mM NaCl) at room temperature. The blots 
were incubated with approximately 5 X 106 c.p.m. of nick- 
translated 32P-labelled DNA in 10 ml of DNA-binding buffer 
for 3 0 minutes. Blots were then washed three times (10 
minutes each) with DNA-binding buffer prior to analysis by 
autoradiography.
159
Reproduced with permission o f the copyright owner. Further reproduction prohibited w ithout permission.
LITERATURE CITED
Abate, C., D. Luyk, R. Gentz, F.J. Rauscher III and T. 
Curran. 1990. Expression and purification of the leucine 
zipper and DNA-binding domains of Fos and Jun: Both Fos and 
Jun contact DNA directly. Proc. Natl. Acad. Sci. USA 87: 
1032-1036.
Abate, C., L. Patel, F.J. Rauscher III, and T. Curran.
1990b. Redox regulation of Fos and Jun DNA-binding activity 
in vitro. Science 249:1157-1161.
Abel, T. and T. Maniatis. 1989. Action of leucine zippers. 
Nature 1989: 24-25.
Ackerman, P. and N. Osherhoff. 1989. Regulation of casein 
kinse II activity by epidermal growth factor in human A-431 
carcinoma cells. J. Biol. Chem. 264:11958-11965.
Adams, A. 1987. Replication of latent Epstein-Barr virus 
genomes in Raji cells. J. Virol. 61:1743-1746.
Agre, P., P.F. Johnson, and S.L. McKnight. 1989. Cognate DNA 
binding specificity retained after leucine zipper exchange 
between GCN4 and C/EBP. Science. 246: 922-925.
Alsip, G.R., Y. Ench, C.V. Sumaya and r .n . Boswell. 1988. 
Increased Epstein-Barr virus DNA in oropharyngeal secretions 
from patients with AIDS, AIDS related complex or 
asymptomatic human immunodeficiency virus infections. J. 
Infect. Dis. 157:1072-1076.
Angel, P., E.A. Allegretto, S., Okino, K. Hatori, W.J.
Boyle, T. Hunter, and M. Karin. 1988a. Oncogene jun encodes 
a sequence-specific trans-activator similar to AP-1. Nature 
332:166-171.
Angel, P. K. Hattori, T. Smeal, and M. Karin. 1988b. The jun 
proto-oncogene is positively autoregulated by its product, 
Jun/AP-1. Cell 55:875-885.
Angel, P., M. Imagawa, R. Chiu, B. Stein, R.J. Imbra, H.J. 
Rahmsdorf, C. Jonat, P. Herrlich, P., and M.Karin.
1987.Phorbol ester-inducible genes contain a common cis 
element recognized by a TPA-modulated trans-acting factor. 
Cell 49:729-739.
Auewrx, J. and P. Sassone-Corsi. 1991. IP-1: A dominant 
inhibitor of Fos/Jun whose activity is modulated by 
phosphorylation. Cell 64:983-993.
160
Reproduced with permission o f the copyright owner. Further reproduction prohibited w ithout permission.
Barbosa, M.G., c. Edmonds, C. Fisher, J.T. Schiller, D.R. 
Lowy and K.H. Vousden. 1990. The region of the HPV E7 
oncoprotein homologous to andenovirus Ela and SV40 large T 
antigen contains separate domains for Rb binding and casein 
kinase II phosphorylation. EMBO J. 9:153-160.
Bauer, G., U. Birnbaum, P. Eofler, and C.H. Heldin. 1985. 
EBV-inducing factor from platelets exhibits growth-promoting 
activity for NIH 3T3 cells. EMBO J. 4:1957-1961.
Baumann, R.P., E. Grogan, M. Ptashne and G. Miller. 1991. 
ZEBRA/VP16 is a uniquely powerful transactivator and inducer 
of Epstein-Barr virus proteins, manuscript in preparation.
Beato, M. 1989. Gene regulation by steroid hormones. Cell 
56:335-344.
Benbrook, D.M. and N.C. Jones. 1990. Heterodimer formation 
between CREB ad JUN proteins. Oncogene 5: 295-302.
Biedenkapp, H., U. Borgmeyer, A.E. Sippel and K.H. 
Klempnauer. 1988. Viral mvb oncogene encodes a sequence- 
specific DNA-binding activity. Nature 335:835-837.
Biggin, M., M. Bodescot, M. Perricaudet, and P. Farrell.
1987. Epstein-Barr virus gene expression in P3HR1- 
superinfected Raji cells. J. Virol. 61:3120-3132.
Blackwell, T.K., L. Kretzner, E.M. Blackwood, R. N.
Eisenman, H. Weintraub. 1990. Science 250:1149.
Blackwood, E.M. and R.N. Eisenman. 1991. Max: A helix-loop- 
helix zipper protein that forms a sequence-specific DNA 
binding complex with Myc. Nature. 251:1211-1217.
Bornkamm, G. H. Delius, U. Zimber, J. Hudewentz and M. 
Epstein. 1980. Comparison of Epstein-Barr virus strains of 
different origin by analysis of the viral DNAP. J. Virol. 
35:603-618.
Bornkamm, G.W., J. Hudenwentz, U.K. Freese, and U. Zimber. 
1982. Deletion of the nontransforming Epstein-Barr virus 
strain P3HR-1 causes fusion of the large internal repeat to 
the DSL region. J. Virol. 43:952-968.
Bowen, B. J. Steinberg, U.K., Laemmli and H. Weintraub.
1980. Nuc. Acids Res. 8:1-20.
Boyle, W.J., T. Smeal, L.H.K. Defize, P. Angel, J.R.
Woodgett, M. Karin, and T. Hunter. 1991. Activation of 
protein kinase C decreases phophorylation of c-Jun at sites
161
Reproduced with permission o f the copyright owner. Further reproduction prohibited w ithout permission.
that negatively regulate its DNA-binding activity. Cell. 
64:573-584.
Burnette, W. N. 1981. "Western blotting": electrophoretic 
transfer of proteins from sodium dodecyl sulfate- 
polyacrylamide gels to unmodified nitrocellulose and 
radiographic detection with an antibody and radioiodinated 
protein A. Anal Biochem. 112:195-203.
Calender, A., M. Billaud, J.P. Aubry, J. Bauchereau, M. 
Vuillaume, and G. M. Lenoir. 1987. Epstein-Barr virus 
(EBV) induces expression of B-cell activation markers on in 
vitro infection of EBV-negative B-lymphoma cells. Proc. 
Natl. Acad. Sci. USA 84:8060-8064.
Candido, E.P.M., R. Reeves, and J.R. Davie. 1978. Sodium 
butyrate inhibits histone deacetylation in cultured cells. 
Cell 14:105-113.
Carey, M., M. Ptashne and G. Hiller. 1991. Transcriptional 
Synergy by the Epstein Barr Virus Transactivator ZEBRA, 
manuscript in preparation.
Carroll, D. and D.R. Marshak. 1989. Serum stimulation of 
cell growth causes oscillations in casein kinase II 
activity. J.B.C. 264:7345-7348.
Carroll, D., N. Santoro, and D.R. Marshak. 1988. Regulating 
cell growth: casein kinase II dependent phosphorylation of 
nuclear oncoproteins. Cold Spring Harbor Symp. 53:91-95.
Chang, Y.-N., D. L.-Y. Dong, G.S. Hayward, and S.D. Hayward.
1990. The Epstein-Barr Virus Zta transactivator: a member of 
the bZIP family with unique DNA-binding specificity and a 
dimerization domain that lacks the characteristic heptad 
leucine zipper motif. J. Virol. 64: 3358-3369.
Chavrier, P., H. Gruffat, A. Chevallier-Greco, M. Buisson, 
and A. Sergeant. 1989. The Epstein-Barr virus (EBV) early 
promoter DR contains a cis-acting element responsive to the 
EBV trans-activator EB1 and an enhancer with constitutive 
and inducible activities. J. Virol. 63:607-614.
Chevallier-Greco, A., H. Gruffat, E. Manet, A. Calender, and 
A. Sergeant. 1989. The Epstein-Barr virus (EBV) DR enhancer 
contains two functionally different domains: domain A is 
constitutive and cell specific, domain B is transactivated 
by the EBV early protein R. J. Virol. 63:615-623.
Chevallier-Greco, A., E. Manet, P. Chavrier, C. Mosnier, 
J.Daillie, and A. Sergeant. 1986. Both Epstein-Barr virus 
(EBV) encoded trans-acting factors, EB1 and EB2, are
162
Reproduced with permission o f the copyright owner. Further reproduction prohibited w ithout permission.
required to activate transcription from an EBV early 
promoter. EMBO J. 5:3243-3249.
Chirgwin, J.M., A.E. Przybyla, R.J. MacDonald, and W.J. 
Rutter. 1979. Isolation of biologically active ribonucleic 
acid from sources enriched in ribonuclease. Biochemistry 
18:5294-5301.
Chiu, R., P. Angel and M. Karin. 1989. Jun-B differs in its 
biological properties from, and is a negative regulator of, 
c-Jun. Cell 59:979-986.
Cho, M.S., G. W. Bornkamm, and H. zur Hausen. 1984. 
Structure of defective DNA molecules in Epstein-Barr virus 
preparations from P3HR-1 cells. J. Virol. 51:199-207.
Church, G., and W. Gilbert. 1984. Genomic Sequencing.
Proc. Natl. Acad. Sci. USA 81:1991-1995.
Cohen, P. and P.T.W. Cohen. 1989. Protein phosphatases come 
of age. J. Biol. Chem. 264:21435-21438.
Countryman, J., H. Jenson, R. Seibl, H. Wolf, and G. Miller.
1987. Polymorphic proteins encoded within BZLF1 of 
defective and standard Epstein-Barr viruses disrupt latency. 
J. Virol. 61:3672-3679.
Countryman, J. and G. Miller. 1985. Activation of expression 
of latent Epstein-Barr herpesvirus after gene transfer with 
a small cloned subfragment of heterogeneous viral DNA. Proc, 
Natl. Acad. Sci. USA 81:7632-7636.
Cox, M.A., J. Leahy, and J.M. Hardwick. 1990. An enhancer 
within the divergent promoter of Epstein-Barr virus responds 
synergistically to the R and Z transactivators. J. Virol. 
64:313-321.
Curran, T. and B.R. Franza. 1988. Fos and Jun: The AP-1 
Connection. Cell 55: 395-397.
Dang, C.V., H. van Dam, M. Buckmire, and W.M.F. Lee. 1989. 
DNA-binding domain of human c-Muc produced in Escherichia 
coli. Mol. and Cell. Biol. 9:2477-2486.
de Schryver, A., S. Friberg, Jr., G. Klein, W. Henle, G. 
Henlo, G. De The, P. Clifford, and H.C. Ho. 1969. Epstein 
Barr virus associated antibody patterns in carcinoma of the 
postnasal space. Clin. Exp. Immun. 5:443-459.
Delius, H. and G. Bornkamm. 1978. Heterogeneity of Epstein- 
Barr virus III. Comparison of a transforming and a 
nontransforming virus by partial denaturation mapping of
163
Reproduced with permission o f the copyright owner. Further reproduction prohibited w ithout permission.
their DNAs. J. Virol. 27:81-89.
Deutsch, P.J., J.P. Hoeffler, J.L. Jameson, and J.F.
Habener. 1988. Cyclic AMP and phorbol ester-stimulated 
transcription mediated by similar DNA elements that bind 
distinct proteins. Proc. Natl. Acad. Sci. USA 85:7922-7926.
Dieckmann, C.L. and A. Tzagaloff. 1985. J. Biol. Chem. 
260:1513-1520.
Dostatni, N. P. Thierry and M. Yaniv. 1988. A dimer of BPV-1 
E2 containing a protease resistant core interacts with its 
DNA target. EMBO J. 7:3807-3816.
Dwarki, V.J., M. Montminy, and I.M. Verma. 1990. Both the 
basic region and the 'leucine zipper' domain of the cyclic 
AMP response element binding (CREB) protein are essential 
for transcriptional activation. EMBO J. 9:225-232.
Edelman, A.M., D.A. Blumenthal, and E.G. Krebs. 1987.
Protein serine and threonine kinases. Ann. Rev. Biochem. 
56:567.
Farrell, P.J., D.T. Rowe, C.M. Rooney, and T. Kouzarides.
1989. Epstein-Barr virus BZLF1 trans-activator specifically 
binds to a consensus AP-1 site and is related to c-fos. EMBO 
J. 8:127-132.
Feinberg, A., and B. Vogelstein. 1983. A technique for 
radiolabeling DNA restriction endonuclease fragments to high 
specific activity. Analytical Biochemistry 132:6-13.
Fingeroth, J.D., J.J. Weiss, T.F. Tedder, J.L. Strominger,
P.A. Biro and D.T. Fearon. 1984. Epstein-Barr virus receptor 
of human B lymphocytes is the C3d receptor CR2. Proc. Natl. 
Acad. Sci. USA 81:4510-4514.
Flemington, E. and S. Speck. 1990a. Identification of 
phorbol ester respnse elements in the promoter of Epstein- 
Barr virus putative lytic switch gene BZLF1. J. Virol. 
64:1217-1226.
Flemington, E. and S. Speck. 1990b. Autoregulation of 
Epstein-Barr virus putative lytic switch gene BZLF1. J.
Virol. 64:1227-1232.
Flemington, E. and S.H. Speck. 1990c. Evidence for coiled- 
Coil dimer formation by an Epstein-Barr virus transactivator 
that lacks a heptad repeat of leucine residues. Proc. Natl. 
Acad. Sci. USA 87:9459-9463.
Flemington, E. and S.H. Speck. 1990d. Epstein-Barr virus
164
Reproduced with permission o f the copyright owner. Further reproduction prohibited w ithout permission.
BZLF1 trans activator induces the promoter of a cellular 
cognate gene, c-fos. J. Virol. 64:4549-4552.
Frade, R., M. Barel, B. Ehlin-Henriksson and G. Klein. 1985. 
gpl40, the C3d receptor of human B lymphocytes, is also thee 
Epstein-Barr virus receptor. Proc. Natl. Acad. Sci. USA 
82:1490-1493.
Fried, M. and D. Crothers. 1981. Equilibrium and kinetics of 
lac repressor-operator interactions by polyacrylamide gel 
electrophoresis. Nucl. Acids Res. 9:3047-3060.
Gentz, R., F.J. Rauscher, C. Abate, and T. Curran. 1989. 
Parallel association of Fos and Jun leucine zippers 
juxtaposes DNA binding domains. Science 243: 1695-1699.
Giot, J.-f., E. Mikaelian, H. Buisson, E. Manet, I. Joab, 
J.-c. Nicolas and A. Sergeant. 1991. Transcriptional 
interference between the EBV transcription factors EB1 and 
R: both DNA-binding and activation domains of EB1 are 
required. Nuc. Acids. Res. 19:1251-1258.
Giri, I. and M. Yaniv. 1988. Structural and mutational 
analysis of E2 trans-activating proteins of papillomaviruses 
reveals three distinct functional domains. EMBO J. 7: 2823- 
2829.
Given, D., D. Yee, K. Griem and E. Kieff. 1979. DNA of 
Epstein-Barr virus. V. Direct repeats of the ends of EBV 
DNA. J. Virol. 30:852-862.
Goodman, S.R., C. Prezyna, and W.C. Benz. 1978. Two Epstein- 
Barr virus-associated DNA polymerase activities. J. Biol. 
Chem. 253:8617-8628.
Gradoville, L., E. Grogan, N. Taylor, and G. Miller. 1990. 
Differences in the extent of activation of Epstein-Barr 
virus replicative gene expression among four non-producer 
cell lines stably transformed by oriP/BZLFl plasmids.
Virol. 178:345-354.
Grasser, F.A., K.H. Scheidtmann, P.T. Tuazon, J.A. Traugh 
and G. Walter. 1988. In vitro phosphorylation of SV40 large 
T antigen. Virology 165:13-22.
Greenspan, J.S., D. Greenspan, E.T. Lennette et al. 1985. 
Replication of Epstein-Barr virus within the epithelial 
cells of oral "hairy" leukoplakia, and AIDS-associated 
lesion. N. Eng. J. Med. 313:1564-1571.
Hammerschmidt, W. and B. Sugden. 1988. Identification and 
characterization of orilyt, a lytic origin of replication of
165
Reproduced with permission o f the copyright owner. Further reproduction prohibited w ithout permission.
Epstein-Barr virus. Cell 55:427-433.
Hampar, B., A. Tanaka, M. Nonoyama, and J. Derge. 1974. 
Replication of resident repressed Epstein-Barr virus genomes 
during the early S phase. (S-l period) of non-producer Raji 
cells. Proc. Natl. Acad. Sci. USA 71:631-633.
Hardwick, J.M., P.M. Lieberman, and S.D. Hayward. 1988. A 
new Epstein-Barr virus transactivator, R, induces 
expression of a cytoplasmic early antigen. J. Virol. 
62:2274-2284.
Hathaway, 6.M. and J.A. Traugh. 1982. Casein kinases: 
multipotential protein kinases. Curr. Top. Cell. Regul. 
21:101.
Hayward, S.D. and J.M. Hardwick. 1991. Epstein-Barr virus 
transactivators and their role in reactivation, in press.
Hayward, S.D. and E. Kieff. 1977. DNA of Epstein-Barr virus. 
II. Comparison of the molecular weights of restriction 
endonuclease fragments of teh DNA of Epstein-Barr virus 
strains and identification of end fragments of the B95-8 
strain. J. Virol. 23:421-429.
Henderson, A., 8. Ripley, M. Heller, and E. Kieff. 1983. 
Chromosome site for Epstein-Barr virus DNAP in a Burkitt 
tumor cell line in lymphocytes growth-transformed in vitro. 
Proc. Natl. Acad. Sci. USA 80:1987-1991.
Henle, G., W. Henle and V. Diehl. 1968. Relation of 
Burkitt's tumor-associated herpes-type virus to infectious 
mononucleosis. Proc. Natl. Acad. Sci. USA 59:94-101.
Henle, W., G. Henle, B. A. Zajac, G. Pearson, R. Waubke, and 
M. Scriba. 1970. Differential reactivity of human serums 
with early antigens induced by Epstein-Barr virus. Science 
169:188-190.
Henle, W., V. Diehl, G. Kohn, H. zur Hausen, and G. Henle.
1967. Herpes type-virus and chromosome marker in normal 
leukocytes after growth with irradiated Burkitt cells. 
Science 157:1064-1065.
Heston, L., M. Rabson, N. Brown, and G. Miller. 1982. New 
Epstein-Barr virus variants from cellular subclones of 
P3J-HR-1 Burkitt lymphoma. Nature (London) 295:160-163.
Hinuma, Y., M. Konn, J.Yamaguchi, and J.T. Grace, Jr. 1967. 
Replication of herpes-type virus in a Burkitt lymphoma cell 
line. J. Virol. 1:1203-1206.
166
Reproduced with permission o f the copyright owner. Further reproduction prohibited w ithout permission.
Hirai, S.-I., B. Bourachot, and H. Yaniv. 1990. Both Jun and 
Fos contribute to transcription activation by the 
heterodimer. Oncogene 5: 39-46.
Hoffman, G., 8.G. Lazarowitz, and S.D. Hayward. 1980. 
Monoclonal antibody against a 250,000 dalton glycoprotein of 
Epstein-Barr virus identifies a membrane antigen and a 
neutralizing antigen. Proc. Natl. Acad. Sci. USA 77:2979- 
2983.
Holley-Guthrie, E.A., E.B. Quinlivan, E.-C. Mar, and S. 
Kenney. 1990. The Epstein-Barr virus (EBV) BMRF1 promoter 
for early antigen (EA-D) is regulated by the EBV 
transactivators, BRLF1 and BZLF1, in a cell-specific manner. 
J. Virol. 64:3753-3759.
Hope, I.A., S. Mahadevan and K. Struhl. 1988. Structural and 
functional characterization of the short acidic 
transcriptional activation region of yeast GCN4 protein. 
Nature 333:635.
Hope, I.A., and K. Struhl. 1987. GCN4, a eukaryotic 
transcriptional activator protein, binds as a dimer to 
target DNA. EMBO J. 6:2781-2784.
Hummel, M. and E. Kieff. 1982. Mapping of polypeptides 
encoded by the Epstein-Barr virus genome in productive 
infection. Proc. Natl. Acad. Sci. USA 79:5698-5702.
Hurley, E.A., S. Agger, J.A. McNeil, J.B. Lawrence, A. 
Calendar, G. Lenoir, and D.A. Thorley-Lawson. 1991. When 
Epstein-Barr virus persistently infects B-cell lines, it 
frequently integrates. J. Virol. 65:1245-1254.
Ivashkiv, L.B., H.-C. Liou, C.J. Kara, W.L. Lamph, I.M.
Verma and L.H. Glimcher. 1990. mXBP/CRE-BP2 and c-Jun form a 
complex which binds to the cyclic AMP, but not to the 12-C- 
tetradecanoylphorbol-13-acetate, response element. Mol. Cell 
Biol. 10:1609-1621.
Jenson, H. B., P. J. Farrell, and G. Miller. 1987.
Sequences of the Epstein-Barr virus (EBV) large internal 
repeat form the center of a 16-kilobase-pair palindrome of 
EBV (P3HR-1) heterogeneous DNA. J. Virol. 61:1495-1506.
Jenson, H., P. Farrell, and G. Miller. 1987. Sequences of 
the Epstein-Barr virus (EBV) large internal repeat form the 
center of a 16-kilobase-pair palindrome of EBV (P3HR-1) 
heterogeneous DNA. J. Virol. 61:1495-1506.
Jenson, H.B., and G. Miller. 1988. Polymorphisms of the 
region of the Epstein-Barr virus genome which disrupts
167
Reproduced with permission o f the copyright owner. Further reproduction prohibited w ithout permission.
latency. Virology 185:549-564.
Jenson, H. B., M. S. Rabson, and 6. Miller. 1986. 
Palindromic structure and polypeptide expression of 3 6 
kilobase pairs of heterogeneous Epstein-Barr virus (P3HR-1) 
DNA. J. Virol. 58:475-486.
Joab, I., H. Triki, J. de Saint Martin, M. Perricaudet, and 
J.C. Nicolas. 1991. Detection of Anti-Epstein-Barr virus 
trans-activator (ZEBRA) antibodies in sera from patients 
with human immunodeficiency virus. J. Infect. Dis. 163:53- 
56.
Johnson, D.A., J.W. Gautsch, J.R. Sportsman, and J.H. Elder.
1984. Improved technique utilizing nonfat dry milk for 
analysis of proteins and nucleic acids transferred to 
nitrocellulose. Gene Anal. Techn. 1:3-8.
Kara, C.J., H.-C. Liou, L.B. Ivashkiv and L.H. Glimcher.
1990. A cDNA for a human cyclic AMP response element-binding 
protein which is distinct from CREB and expressed 
preferentially in brain. Mol. Cell. Biol. 10:1347-1357.
Karlin, S. and V. Brendel. 1990. Charge configurations in 
oncogene products and transforming proteins. Oncogene 5: 85- 
95.
Karlund, J.K. and M.P. Czech. 1988. Insulin-like growth 
factor I and insulin rapidly increase casein kinase II 
activity in BALB/c 3T3 fibroblasts. J. Biol. Chem. 
263:15872-15875.
Katz, B.Z., N. Raab-Traub, and G. Miller. 1989. Latent and 
replicating forms of Epstein-Barr virus DNA in lymphomas and 
lymphoproliterative diseases. J. Inf. Dis. 160:589-598.
Katz, D.A., J.L. Kolman, N. Taylor, R. Baumann, and G. 
Miller. 1991. Viral proteins associated with the Epstein- 
Barr replication activator. Manuscript in preparation.
Kenney, S., E. Holley-Guthrie, E. Byrd Quinlivan, D. Gutsch, 
T. Bender, J.-f. Giot and A. Sergeant. 1991. The cellular 
oncogene, c-mvb can interact synergistically with the 
Epstein-Barr virus BZLF1 transactivator in lymphoid cells. 
Mol. and Cell. Biol., submitted.
Kenney, S., J. Kamine, E. Holley-Guthrie, J.C. Lin, E.C.
Mar, and J. Pagano. 1989a. The Epstein-Barr virus (EBV) gene 
BZLF1 immediate-early gene product differentially affects 
latent versus productive EBV promoters. J. Virol. 63:1729- 
1736.
168
Reproduced with permission o f the copyright owner. Further reproduction prohibited w ithout permission.
Kenney, S., E. Holley-Guthrie, E.-C. Mar and M. Smith.
1989b. The Epstein-Barr virus BMLF1 promoter contains an 
enhancer element that is responsibe to the BZLF1 and BRLF1 
transactivators. J. Virol. 63:3878-3883.
Kenney, S., J. Kamine, D. Markovitz, R. Fenrick, R. and J. 
Pagano. 1988. An Epstein-Barr virus immediate-early gene 
product trans-activates gene expression from the human 
immunodeficiency long terminal repeat. Proc. Natl. Acad. 
Sci.USA 85:1652-1656.
Kintner, C.R. and B. Sugden. 1979. The structure of the 
termini of the DNA of Epstein-Barr virus. Cell 17:661-671.
Kleid, D.G., D. Yansura, B. Small, D. Dowbenko, D.M. Moore, 
M.J. Grubman, P.D. McKercher, D.O. Morgan, B.H. Robertson, 
and H.L. Bachrach. 1981. Cloned viral protein vaccine for 
foot and mouth disease responses in cattle and swine. 
Science 214: 3834-3838.
Klempnauer, K.-H., H. Arnold, and H. Biedenkapp. 1989. 
Activation of transcription by v-myb: evidence for two 
different mechanisms. Genes and Dev. 3:1582-1589.
Klempnauer, K.-H. and A.E. Sippel. 1987. The highly 
conserved amino-terminal region of the protein encoded by 
the v-myb oncogene functions as a DNA-binding domain. EMBO 
J. 6:2719-2725.
Kolman, J., N. Taylor, and G. Miller. 1990. Heterodimers of 
the ZEBRA and Fos basic domains bind DNA with the 
specificity of ZEBRA. Manuscript in preparation.
Kouzarides, T. and E. Ziff. 1989. Leucine zippers of fos, 
jun and GCN4 dictate dimerization specificity and thereby 
control DNA binding. Nature 340:568-571.
Kouzarides, T. and E. Ziff. 1988. The role of the leucine 
zipper in the fos-jun interaction. Nature 336: 646-651.
Krebs, E.G., R.N. Eiseenman, E.A. Kuenzel, D.W. Litchfield, 
R.J. Lozeman, B. Luscher and J. Sommercorn. 1988. Casein 
kinase II as a potentially important enzyme concerned with 
signal transduction. Cold Spring Harb. Symp. Quant. Biol. 
53:77-84.
Keunzel, E.A., J.A. Mulligan, J. Sommercorn and E.G. Krebs.
1987. Substrate specificity determinants for casein kinase 
II as deduced from studies with synthetic peptides. J. Biol. 
Chem. 262:9136.
Laemmli, U.K. 1970. Cleavage of structural proteins during
169
Reproduced with permission o f the copyright owner. Further reproduction prohibited w ithout permission.
the assembly of the head of bacteriophage T4. Nature 
227:680-685.
Landschulz, W.H., P.F. Johnson, and S.L. McKnight. 1988. The 
DNA-binding domain of the rat liver nuclear protein C/EBP is 
bipartite. Science 243:1681-1688.
Laux, 6., K. Freese, R. Fischer, A. Polack, E. Hofler, and 
G. Bornkamm. 1988. TPA-Inducible Epstein-Barr virus genes 
in Raji cells and their regulation. Virology 162:503-507.
Lee, W., P. Mitchell, and R. Tjian. 1987. Purified 
transcription factor AP-1 interacts with TPA-inducible 
enhancer elements. Cell 49:741-752.
Lieberman, P.M. and A.J. Berk. 1990. In vitro 
transcriptional activation, dimerization, and DNA-binding 
specificity of the Epstein-Barr virus Zta protein. J. Virol. 
64:2560-2568.
Lieberman, P.M., M.J. Hardwick, J. Sample, G.S. Hayward, and 
S.D. Hayward. 1990. The Zta transactivator involved in 
induction of lytic cycle gene expression in Epstein-Barr 
virus- infected lymphocytes binds to both AP-1 and ZRE sites 
in target promoter and enhancer regions. J. Virol. 64:1143- 
1155.
Lieberman, P.M., J.M. Hardwick, and S.D. Hayward. 1989. 
Responsiveness of the Epstein-Barr virus Notl repeat 
promoter to the Z-transactivator is mediated in a cell-type 
specific manner by two independent signal regions. J.
Virol. 63:3040-3050.
Lindahl, T., A. Adams, B. Bjursell, G. Bornkamm, C. Kaschka- 
Dierich and U. Jehn. 1976. Covalently closed circular 
duplex DNA of Epstein-Barr virus in a human lymphoid cell 
line. J. Mol. Biol. 102:511-530.
Luka, J., B. Kallin, and G. Klein. 1979. Induction of the 
Epstein-Barr virus (EBV) cycle in latently infected cells by 
n-butyrate. Virology 94:228-231.
Luthman, H., and G. Magnusson. 1983. High efficiency 
polyoma DNA transfection of chloroquine treated cells. 
Nucleic Acids Res 11:1295-1308.
Luscher, B. and R.N. Eisenman. 1990a. New light on Myc and 
Myb. part I. Myc. Genes & Dev. 4:2025-2035.
Luscher, B. and R.N. Eisenman. 1990b. New light on Myc and 
Myb. part II. Myb. Genes & Dev. 4:2235-2241.
170
Reproduced with permission o f the copyright owner. Further reproduction prohibited w ithout permission.
Luscher, B., E. Christenson, D.W. Litchfield, E.G. Krebs and 
R.N. Eisenman. 1990. Myb DNA binding inhibited by 
phosphorylation at a site deleted during oncogenic 
activation. Nature 344:517-521.
Luscher, B., E.A. Kuenzel, E. Krebs and R.N. Eisenman. 1989. 
Myc oncoproteins are phosphorylated by casein kinase II.
EMBO 8:1111-1119.
Ma, J. and M. Ptashne. 1987. Deletion analysis of GAL4 
defines two transcriptional activating segments. Cell 
48:847.
Mallon, R., J. Borkowski, R. Albin, S. Pepitoni, J. Schwartz 
and E. Kieff. 1990. The Epstein-Barr virus BZLF1 gene 
product activates the human immunodeficiency virus type 1 5' 
long terminal repeat. J. Virol. 64:6282-6285.
Manak, J.R., N.D. Bisschop, R.M. Kris, and R. Prywes. 1990. 
Casein kinase II enhances the DNA binding activity of serum 
response factor. Genes & Dev. 4:955-967.
Manet, E., H. Gruffat, M.C. Trescol-Biemont, N. Moreno, P. 
Chambard, J.F. Giot, and A. Sergeant. 1989. Epstein-Barr 
virus bicistronic mRNAs generated by facultative splicing 
code for two transcriptional trans-activators. EMBO J. 
8:1819-1826.
Maniatis, T., E.F. Fritsch, and J. Sambrook, Eds. 1982. 
Molecular Cloning. Cold Spring Harbor Laboratory.
Marin, O. F. Meggio, F. Marchiori, G. Borin and L.A. Pinna.
1986. Site specificity of casein kinase-2 from rat liver 
cytosol. Eur. J. Biochem. 160:239.
Matsuo, T., M. Heller, L.Petti, E. O'Shiro, and E. Kieff.
1984. Persistence of the entire Epstein-Barr virus genome 
integrated into human lymphocyte DNA. Science 226:1322-1325.
McBride, A.A., J.C. Byrne, and P.M. Howley. 1989. E2 
polypeptides encoded by bovine papillomavirus type 1 form 
dimers through the common carboxyl-terminal domain: 
transactivation is mediated by the conserved amino-terminal 
domain. Proc. Natl. Acad. Sci. USA 86: 510-514.
Meek, D.W., S. Simon, U. Kikkawa, and W. Eckhart. 1990. The 
P53 tumor suppressor protein is phosphorylated at serine 389 
by casein kinase II. Embo J. 9:3253-3260.
Melton, D.A., P.A. Krieg, M.R. Rebagliati, T. Maniatis, K. 
Zinn, and M.R. Green. 1984. Efficient in vitro synthesis of 
biologically active RNA and and RNA hybridization probes
171
Reproduced with permission o f the copyright owner. Further reproduction prohibited w ithout permission.
from plasmids containing a bacteriophage SP6 promoter. 
Nucleic Acids Res. 12:7035-7056.
Hiller, G. 1990a. Epstein-Barr virus: biology, pathogenesis, 
and medical aspects.in Virology 2nd edition, ed B. N.
Fields, D.M. Knipe et al. Raven Press, Ltd., New York, 1921- 
1958.
Miller, G. 1990b. The switch between latency and replication 
of Epstein-Barr virus. J. Inf. Dis. 161:833-844.
Miller, G., L. Heston, and J. Countryman. 1985. P3HR-1 
Epstein-Barr virus with heterogeneous DNA is an independent 
replicon maintained by cell-to-cell spread. J. Virol. 
54:45-52.
Miller, G., M. Rabson, and L. Heston. 1984. Epstein-Barr 
virus with heterogeneous DNA disrupts latency. J. Virol. 
50:174-182.
Miller, G., T. Shope, H. Lisco, D. Stitt and M. Lipman.
1972. Epstein-Barr virus: transformation, cytopathic 
changes, and viral antigens in squirrel monkeys and marmoset 
leukocytes. Proc. Natl. Acad. Sci. USA 69:383-387.
Miller, G., J.F. Enders, H. Lisco, and H.I. Kohn. 1969. 
Establishment of lines from normal human blood leukocytes by 
co-cultivation with a leukocyte line derived from a leukemic 
child. N. Eng. J. Med. 212:452-455.
Nakabeppu, Y. and D. Nathans. 1991. A naturally occurring 
truncated form of FosB that inhibits Fos/Jun transcriptional 
activity. Cell 64:751-759.
Nakabeppu, Y. and D. Nathans. 1989. The basic region of Fos 
mediates specific DNA binding. EMBO J. 8:3833-3841.
Nakabeppu, Y., K. Ryder, D. Nathans. 1988. DNA binding 
activities of three murine Jun proteins: stimulation by Fos. 
Cell 55:907-915.
Neuberg, M., J. Adamkiewicz, J.B. Hunter, and R. Muller.
1989a. A Fos protein containing the leucine zipper forms a 
homodimer which binds to the API binding site. Nature 
341:243-245.
Neuberg, M., M. Schuermann, J.B. Hunter, and R. Muller.
1989b. Two functionally different regions in Fos are 
required for the sequence-specific DNA interaction of the 
Fos/Jun protein complex. Nature 338:589-590.
Niederman, J., R. McCollum, G. Henle and W. Henle. 1968.
172
Reproduced with permission o f the copyright owner. Further reproduction prohibited w ithout permission.
Infectious mononucleosis; clinical manifestations in 
relation to EB virus antibodies. J.A.M.A. 203:205-209.
O’Shea, E.K., R. Rutkowski, R.and P.S. Kims. 1989. Evidence 
that the leucine zipper is a coiled-coil. Science 243:538- 
543.
Packham, G., A. Economou, C.M. Rooney, D.T. Rowe and P.J. 
Farrell. 1990. Structure and Function of the Epstein-Barr 
Virus BZLF1 Protein. J. Virol. 64:2110-2116.
Papavassiliou, A.G., K.W. Wilcox, and s.J. Silverstein.
1991. The interaction of ICP4 with cell/infected-cell 
factors and its state of phosphorylation modulate 
differential recognition of leader sequences in herpes 
simplex virus DNA. EMBO J. 10:397-406.
Patton, D., P.Shirley, N. Raab-Trab, L. Resnick and J.W. 
Sixbey. 1990. Defective viral DNA in Epstein-Barr virus- 
associated oral hairy leukoplakia. J. Virol. 64:397-400.
Pope, j.H., W. Scott,and H. Mik. 1969. Identification of the 
filterable leukocyte transforming factor of QIMR-WIL cells 
as herpes-like virus. Int. J. Cancer 4:255-260.
Prendergast, G.C. and E.B. Ziff. 1989. DNA-binding motif. 
Nature 341: 392.
Pritchett,, R., D. Hayward, and E. Kieff. 1975. DNA of 
Epstein-Barr virus. I. Comparative studies ofthe DNAP of 
Epstein-Barr virus from HR-1 and B95-8 cells: size, 
structure and relatedness. J. Virol. 15:556-569.
Ptashne, M. 1988. How eukaryotic transcriptional activators 
work. Nature 335:683-689.
Quinlivan, E.B., E. Holley-Guthrie, E.C. Mar, M.S. Smith, 
and S. Kenney. 1990. The Epstein-Barr virus BRLF1 immediate- 
early gene product transactivates the human immunodeficiency 
virus type I long terminal repeat by a mechanism which is 
enhancer dependent.
Raab-Traub, N., R. Hood, C-S. Yang, B Henry II, and J.S. 
Pagano. 1983. Epstein-Barr virus transcription in 
nasopharyngeal carcinoma. J. Virol. 48:580-590.
Rabson, M., L. Heston, and G. Miller. 1983. Identification 
of a rare Epstein-Barr virus variant that enhances early 
antigen expression in Raji cells. Proc. Natl. Acad. Sci.
USA 80:2 ~R 
762-2766.
173
Reproduced with permission o f the copyright owner. Further reproduction prohibited w ithout permission.
Rabson, M., L. Gradoville, L. Heston and G. Miller. 1982. 
Non-immortalizing P3JHR-1 Epstein-Barr virus: a deletion 
mutant of its transforming parent Jijoye. J. Virol. 44:834- 
844.
Rasmussen, R. D. Benvegnu, E.K. O'Shea, p.s. Kim and T. 
Alber. 1991. X-ray scattering indicates that the leucine 
zipper is a coiled coil. Proc. Natl. Acad. Sci. USA 88:561- 
564.
Rauscher, F.J., P.J. Boulalas, B.R. Franza, Jr. and T. 
Curran. 1988. Fos and Jun bind cooperatively to the AP-1 
site: reconstruction in vitro. Genes Dev. 2:1687-1699.
Rawlins, D.R., G. Milman, S.D. Hayward, and G.S. Hayward.
1985. Sequence specific DNA binding of the Epstein-Barr 
virus nuclear antigen (EBNA-1) to clustered sites in the 
plasmid maintenance region. Cell 42:859-868.
Rigby, P., M. Diekmann, C. Rhodes, and P. Berg. 1977. 
Labelling deoxyribonucleic acid to high specific activity in 
vitro by nick translation with DNA polymerase I. J. Mol. 
Biol. 113:237-251.
Rihs, H.-P., D.A. Jans, H.Fan, and R. Peters. 1991. The rate 
of nuclear cytoplasmic protein transport is determined by 
the casein kinsae-II site flanking the nuclear localization 
sequence of the SV40 T-antigen. Embo J. 10:633-639.
Risse, G., K. Jooss, N. Manfred, H.J. Bruiler, and R.
Muller. 1989. Asymmetrical recognition of the palindromic 
API binding site (TRE) by Fos protein complexes. EMBO J. 
8:3825-3832.
Robinson, J., A. Frank, E. Henderson, J. Schweitzer and G. 
Miller. 1979. Surface markers and size of lymphocytes in 
human umbilical cord blood stimulated into deoxyribonucleic 
acid synthesis by Epstein-Barr virus. Infect. Immunol. 
26:225-231.
Rogers, R.P. and S.H. Speck. 1990. Bidirectional 
transcription of the Epstein-Barr virus major internal 
repeat. J. Virol. 64:2426-2429.
Rooney, C., J.G. Howe, S.H. Speck, and G. Miller. 1989a. 
Influences of Burkitt's lymphoma and primary B cells on 
latent gene expression by the nonimmortalizing P3J-HR-1 
strain of Epstein-Barr virus. J. Virol. 63:1531-1539.
Rooney, C., D.T. Rowe, T. Ragot, and P.J. Farrell. 1989b.
The spliced BZLF1 gene of Epstein-Barr virus (EBV) 
transactivates an early EBV promoter and induces the virus
174
Reproduced with permission o f the copyright owner. Further reproduction prohibited w ithout permission.
productive cycle. J. Virol. 63:3109-3116.
Rooney, c . ,  N. Taylor, J. Countryman, H. Jenson, J. Kolman, 
and 6. Hiller. 1988. Genome rearrangements activate the 
Epstein-Barr virus gene whose product disrupts latency.
Proc. Natl. Acad. Sci. USA. 85:9801-9805.
Rowe, D. T., P. J. Farrell, and G. Miller. 1987. Novel 
nuclear antigens recognized by human sera in lymphocytes 
latently infected by Epstein-Barr virus. Virology 
156:153-162.
Rowe, D.T., H. Rowe, G.I. Evan, L.E. Wallace, P.J. Farrell, 
and A.B. Rickinson. 1986. Restricted expression of EBV 
latent genes and the lymphocyte-detected membrane antigen in 
Burkitt's lymphoma cells. EMBO J. 5:2599-2607.
Sassone-Corsi, P., L.J. Ransone, W.W. Lamph, and I.M. Verma.
1988. Direct interaction between fos and jun nuclear 
oncoproteins: role of the 'leucine zipper' domain. Nature 
336: 692-695.
Scheidtmann, K.H., D.M. Virshup, and T.J. Kelly. 1991. 
Protein phosphatase 2A dephosphorylates simian virus 40 
large T antigen specifically at residues involved in 
regulation of DNA binding activity. J Virol. 65:2098-2101.
Schuermann, M., H. Neuberg, J.B. Hunter, T. Jenuwein, R.P. 
Ryseck, R. Bravo and R. Muller. 1989. The leucine repeat 
motif in Fos protein mediates complex formation with Jun/API 
and is required for transformation. Cell 56: 507-516.
Schutte, J., J. Viallet, M. Nau, S. Segal, J. Fedorko and J. 
Minna. 1989. iun-B inhibits and c-fos stimulaates the 
transforming and trans-activating activities of c-iun. Cell 
59:987-997.
Sealy, L. and R. Chalkley. 1978. The effect of sodium 
butyrate on histone modification. Cell 14:115-121.
Seibl, R., M. Motz, and H. Wolf. 1986. Strain-specific 
transcription and translation of the BamHI Z area of 
Epstein-Barr Virus. J. Virol. 60:902-909.
Sellers, J.W. and K.Struhl. 1989. Changing Fos oncoprotein 
to a Jun-independent DNA-binding protein with GCN4 
dimerization specificity by swapping 'leucine zippers'. 
Nature 341:74-76.
Simmons, D.T., W. Chou and K. Rodgers. 1986. Phosphorylation 
downregulates the DNA binding activity of Simian virus 40 T 
antigen. J. Virol. 60:888-894.
175
Reproduced with permission o f the copyright owner. Further reproduction prohibited w ithout permission.
Sinclair, A.J., M. Brimmell, F. Shanahan and P. Farrell.
1991. Pathways of activation of the Epstein-Barr virus 
productive cycle. J. Virol. 65:2237-2244.
Sixbey, J.W., D.S. Davis, L.S. Young, L. Hutt-Fletcher, T.F. 
Tedder, and A.B. Rickenson. 1987. Human epithelial cell 
expression of an Epstein-Barr virus receptor. J. Gen. Virol. 
68:805-811.
Sixbey, J.W., S.H. Lemon, and J.S. Pagano. 1986. A second 
site for Epstein-Barr virus shedding: the uterine cervix. 
Lancet 2:1122-1124.
Slice, L.W., and S.S. Taylor. 1989. Expression of the 
catalytic subunit of cAMP-dependent protein kinase in 
Escherichia coli. J. Biol. Chem. 264:20940-20946.
Smith, R.F. and T.F. Smith. 1989. Identification of new 
protein kinase-related genes in three herpesviruses, herpes 
simplex virus, varicella-zoster virus and Epstein-Barr 
virus. J. Virol. 63:450-455.
Sommercorn, J., J.A. Mulligan, F.J. Lozeman and E.G. Krebs.
1987. Activation of casein kinase II in response to insulin 
and to epidermal growth factor. Proc. Natl. Acad. Sci. USA 
84:8834-8838.
Sorger, P.K. and H.C.M. Nelson. 1989. Trimerization of a 
yeast transcriptional activator via a coiled-coil motif.
Cell 59: 807-813.
Sorger, P.K. and H.R.B. Pelham. 1988. Yeast heat shock 
factor is an essential DNA-binding protein that exhibits 
temperature-dependent phosphorylation. Cell 54:855-864.
Stocco, R., G. Sauvageau, and J. Menezes. 1988. Differences 
in Epstein-Barr virus (EBV) receptors expression on various 
human lymphoid targets and their significance to EBV- cell 
interactions. Virus Res. 11:209-225.
Sugden, B., M. Phelps, and J. Domoradski. 1979. Epstein-Barr 
virus DNA is amplified in transformed cells. J. Virol. 
31:590-595.
Summers, W. and G. Klein. 1976. Inhibition of Epstein-Barr 
virus DNA synthesis and late gene expression by 
phosphonoacetic acid. J. Virol. 18:151-155.
Sun, X.-h. and D. Baltimore. 1991. An inhibitory domain of 
E12 transcription factor prevents DNA binding in E12 
homodimers but not in E12 heterodimers. Cell 64:459-470.
176
Reproduced with permission o f the copyright owner. Further reproduction prohibited w ithout permission.
Takada, K., N. Shimizu, S. Sakuma, and Y. Ono. 1986. trans- 
Activation of the latent Epstein-Barr virus (EBV) genome 
after transfection of the EBV DNA fragment. J. Virol. 
57:1016-1022.
Taylor, N., E. Flemington, J.L. Kolman, R.P. Baumann, S.H. 
Speck, and 6. Miller. 1991a. ZEBRA and a Fos-GCN4 chimeric 
protein differ in their DNA binding specificities for sites 
in the Epstein-Barr viral BZLF1 promoter. J. Virol., in 
press.
Taylor, N., J.L Kolman, and G. Miller. 1991b. Heterodimers 
of the ZEBRA and Fos basic domains bind DNA with the 
specificity of ZEBRA. In, EBV and Human Diseases 1990. 
Ablashi, D.V., Huang, A.T., Pagano, J.S., Pearson, G.R. and 
Yang, C.S., editors. Humana Press, Clifton, NJ.
Taylor, N., J. Countryman, C. Rooney, D. Katz, and G.
Miller. 1989. Expression of the BZLF1 latency-disrupting 
gene differs in standard and defective Epstein-Barr viruses. 
J. Virol. 63:1721-1728.
Towbin, H., T. Staehelin and J. Gordon. 1979.
Electrophoretic transfer of proteins from polyacrylamide 
gels to nitrocellulose sheets: procedure and some 
applications. Proc. Natl. Acad. Sci. USA 76:4350-4354.
Tugwood, J.D., W.-H. Lau, S.-Y. Sai-Kio, et al. 1987. 
Epstein-Barr virus specific transcription in normal and 
malignant nasopharyngeal biopsies and in lymphocytes from 
healthy donors and infecrious mononucleosis patients. J.
Gen. Virol. 68:1081-1091.
Turner, R. and R. Tjian. 1989. Leucine repeats and an 
adjacent DNA binding domain mediate the formation of 
functional cFos-cJun heterodimers. Science 243:1689-1694.
Urier, G., M. Buisson, P. Chambard, and A. Sergeant. 1989. 
The Epstein-Barr virus early protein EB1 activates 
transcription from different responsive elements including 
AP-1 binding sites. EMBO J. 8:1447-1453.
Van Straaten, F., R. Muller, T. Curran, C. van Beveren, and
I.M. Verma. 1983. Complete sequence of a human c-onc gene: 
deduced amino-acid sequence of the human c-fos gene protein. 
Proc. Natl. Acad. Sci. USA 80:3183-3187.
Vinson, C.R., P.B. Sigler, and S.L. McKnight. 1989. 
Scissors-grip model for DNA recognition by a family of 
leucine zipper proteins. Science 246:911-916.
177
Reproduced with permission o f the copyright owner. Further reproduction prohibited w ithout permission.
Virshup, D.T., M.6. Kauffman and T.J. Kelly. 1989.
Activation of SV40 DNA replication in vitro by cellular 
protein phosphatase 2A. EMBO J. 8:3891-3898.
Weigel, R. and G. Miller. 1983. Major EB virus-specific 
cytoplasmic transcripts in a cellular clone of the HR-1 
Burkitt lymphoma line during latency and after induction of 
viral replicative cycle by phorbol esters. Virology 125:287- 
298.
Yamamoto, K.K., G.A. Gonzalez, P. Menzel, J. Rivier, and 
M.R. Montminy. 1990. Characterization of a bipartite 
activator domain in transcription factor CREB. Cell 60: 611- 
617.
Yamamoto, K.K., G.A. Gonzalez, W.H. Biggs III, and M.R. 
Montminy. 1988. Phosphorylation-induced binding and 
transcriptional efficacy of nuclear factor CREB. Nature 
334:494-498.
Yates, J., N. Warren, D. Reisman, and B. Sugden. 1984. A 
cis-acting element from the Epstein-Barr viral genome that 
permits stable replication of recombinant plasmids in 
latently infected cells. Proc. Natl. Acad. Sci. USA 81:3806- 
3810.
zur Hausen, H., G. W. Bornkamm, R. Schmidt, and E. Hecker. 
1979. Tumor initiators and promoters in the induction of 
Epstein-Barr virus. Proc. Natl. Acad. Sci. U.S.A. 
76:782-785.
zur Hausen, H., F.J. O'Neill, U.K. Freese, and E. Hecker.
1978. Persisting oncogenic herpesvirus induced by the tumor 
promoter TPA. Nature 272:373-375.
178
Reproduced with permission o f the copyright owner. Further reproduction prohibited w ithout permission.
